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9IBlood coagulation 
The arrest of bleeding (hemostasis) after an injury is the result of interplay 
between the damaged blood vessel, circulating cells (thrombocytes) in the 
blood, and the blood coagulation system. Ultimately, a hemostatic plug is 
formed, which halts bleeding during the repair process of the disrupted 
vessel. In the aftermath, feedback processes will control extension and 
initiate lysis of the blood clot. A central factor in the blood coagulation 
process is thrombin (factor IIa), which is formed from prothrombin after a 
series of enzymatic reactions. Thrombin generation is initiated when small 
amounts of factor VIIa bind to tissue factor (TF), which ordinarily will only 
be exposed to flowing blood after damage to the endothelium (Figure 1).1 
The factor VIIa-TF complex activates factors IX and X, which with the help 
of the activated cofactors VIII and V will convert prothrombin to thrombin 
(Figure 1). Thrombin generation is inhibited by tissue factor pathway inhibitor 
(TFPI), antithrombin and activated protein C (APC). TFPI blocks the tissue 
factor-initiated activation of factors IX and X, and antithrombin inactivates 
factor IX, factor X and prothrombin. APC is formed when thrombin binds to 
thrombomodulin, a receptor on the endothelium, and inactivates cofactors 
V and VIII. Defects in the hemostatic balance maintained by the pro- and 
anticoagulant systems can produce hemorrhagic or thrombotic disease.
Figure 1 Derived with permission from KG Mann. Biochemistry and Physiology 
of Blood Coagulation. Thrombosis and Haemostasis 1999;82:165-174. 
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Venous thrombosis affects 1-2 per 1000 individuals per year.2,3 The most 
frequent clinical manifestation is thrombosis in the deep veins of the leg, 
which may embolize to the lungs. Major consequences can be chronic leg or 
lung problems, which may have a major impact on quality of life4,5, and may 
cause death.6 Numerous risk factors are known to increase the risk of venous 
thrombosis such as hereditary defects in the coagulation system, hormonal 
changes (e.g., pregnancy, use of female hormones), other diseases (e.g., 
malignancy), and physical factors (e.g., inactivity).7 One or more risk factors 
can now be found in one-third of consecutive patients with a first deep venous 
thrombosis.8 Also, one-fourth of all consecutive patients with a first event 
report at least one first-degree relative with venous thrombosis.9 
The first identified hereditary defect in the coagulation system increasing the 
risk of venous thrombosis was antithrombin deficiency10, which was followed 
by the discovery of deficiencies in other natural coagulation inhibitors: protein 
C11 and protein S12. The most common hereditary defects were discovered 
within the last decade: factor V Leiden13 and the prothrombin G20210A 
variant14. Although testing for these defects is common, a positive outcome 
does not always predict or fully explain disease occurrence due to the low 
penetrance of disease associated with these defects. Like many other common 
diseases, venous thrombosis is believed to be a multicausal disease, in which 
one risk factor is seldom sufficient to cause venous disease.15 For example, 
Miletich et al. reported in 1987 that protein C deficiency was quite common 
in the normal population without a detectable association with a risk of 
thrombosis16, whereas in family studies a strong association was found.17,18 
This discrepancy can be explained by the multicausal nature of the disease: 
multiple defects are present within families leading to a familial tendency for 
venous thrombosis (thrombophilia), as shown by Lensen et al.19,20 Familial 
thrombophilia is characterized by a strong family history of venous thrombosis 
with an early age of onset, recurrent events, severe events out of proportion 
to known stimuli, and unusual clinical presentation of the disease.21
Outline of this thesis
This thesis focuses on the risk of venous thrombosis associated with familial 
thrombophilia, and on the search for new genetic risk factors. The results 
of two studies will be described: the European Prospective Cohort on 
Thrombophilia (EPCOT) study and the International Protein C Investigation 
(IPCI).
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IThe European Prospective Cohort on Thrombophilia (EPCOT)
As large studies on the risk of venous thrombosis in families with inherited 
thrombophilia were scarce in the 1990s, whereas the demand for therapeutic 
guidelines was high, it was decided to initiate a European prospective cohort 
study on thrombophilia to obtain reliable risk estimates for first and recurrent 
events. Whereas the primary aim was to estimate the risk of thrombosis, 
secondary aims were to investigate other effects of thrombophilia, such as 
fetal loss, as well as the risk of side effects of treatment, such as hemorrhage 
following anticoagulant therapy. A total of nine thrombosis centers (from 
Barcelona, Bologna, Frankfurt, Glasgow, Leiden, Malmö, Paris, Sheffield and 
Vienna) with long-standing interest in thrombophilia research participated in 
the European Prospective Cohort on Thrombophilia, which was funded by the 
European Union as a Concerted Action. Patients referred to these specialist 
clinics with a deficiency of antithrombin, protein C or protein S, or with factor 
V Leiden were included when they had at least one relative with the same 
familial defect. Relatives with a prothrombotic defect were included regardless 
of their venous thrombosis disease status. As a representation of the normal 
population, partners or friends of the thrombophilic participants were 
included. For each participant, data were gathered at inclusion on previous 
venous events and thrombosis-related characteristics. During prospective 
follow-up, data were collected annually on the occurrence of risk situations 
and events (e.g., venous and arterial events, bleeding episodes and death). 
Inclusion was between March 1994 and September 1997, and prospective 
follow-up was until January 2001. The first chapter (Chapter I) includes the 
reports describing the results from the EPCOT study on the history of venous 
thrombosis before inclusion in the study in all participants (Chapter I.1), the 
risk of a first event during prospective follow-up in the relatives and control 
individuals with no history of venous thrombosis before study entry (Chapter 
I.2), and the risk of a second event during prospective follow-up in relatives 
with a first event before inclusion (Chapter I.3). In chapter I.4 we describe 
the results concerning a secondary aim: the risk of fetal loss during follow-up 
associated with inherited thrombophilia.
The international protein C investigation (IPCI)
Since 1985 a large family (n~800) with protein C deficiency has been studied 
which resides mainly in New England (USA) and Québec (Canada).18 About 
25% of the family members carry a C insertion in exon 6 of the protein C 
gene (3363C mutation), which is associated with protein C deficiency, and 
about 25% of the carriers have developed venous thrombotic disease.18 A 
founder couple from France probably “imported” this 3363C mutation to 
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IQuébec around 1669.22 In 1998, evidence was found for an unknown genetic 
defect influencing the risk of venous thrombosis in this family in interaction 
with protein C deficiency.23 Several genes were tested as candidates for the 
interacting defect, including factor V Leiden and the prothrombin G20210A 
variant, but no evidence was found to support that any of these genes was 
the candidate gene.24 For the prothrombin variant this was an unexpected 
finding as the carrier frequency in this family was high compared with 
the presence in the general Caucasian population (13% versus 1-4%).25 
A subsequent investigation in which the probability of transmission of the 
prothrombin G20210A mutation was estimated among family members 
with or without the protein C mutation or a venous event even suggested a 
protective effect of the prothrombin mutation in the presence of the protein C 
mutation.25 As the prothrombin G20210A mutation has been associated with 
increased prothrombin levels14,26-28, we postulated a potential beneficial effect 
of increased thrombin-mediated activated protein C generation in carriers of 
the prothrombin G20210A mutation. By utilizing a new and highly sensitive 
assay for measuring the concentration of activated protein C in complex with 
protein C inhibitor as a measure of the level of activation of protein C, we 
tested this hypothesis (Chapter I.5). 
To continue the search for unknown genes increasing the risk of venous 
thrombosis, we performed linkage analysis using DNA from plasma samples 
of the protein C deficient kindred.29 Family members were genotyped for 375 
autosomal markers, which were equally spaced across the genome with an 
average marker spacing of 9.4 cM (1 cM~1 million base pairs). Assuming 
that genes in close proximity to a marker will share the inheritance pattern 
of that particular marker, disease genes can be located by identifying those 
markers of which the inheritance pattern matches the inheritance pattern of 
the disease. Linkage analysis on 132 genotyped family members identified 
three potential candidate regions on chromosomes 10, 11 and 18 for a gene 
influencing the risk of venous thrombosis.29 
A correct phenotype definition is crucial in performing linkage analysis. 
Therefore, we developed a questionnaire with detailed questions on venous 
thrombosis to create a more accurate phenotype definition. The questionnaire 
showed a high sensitivity for detecting a history of venous thrombosis 
in patients with venous thrombosis when comparing answers to the 
questionnaire with chart information.30 This questionnaire was then distributed 
among more than 300 family members. However, as we earlier found less 
agreement between the self-reported history and the chart information 
regarding details on venous events in patients with an extensive history of 
venous thrombosis, chart review may still be needed in family members with 
multiple venous events for optimal ascertainment of a detailed thrombosis 
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Ihistory.30 In addition, to extend the phenotype definition, ultrasound 
examinations were performed in family members to search for signs of venous 
thrombosis in the legs of those who were not known to have had venous 
thrombosis.31 
Besides performing linkage analysis with venous disease as the outcome, 
which is either present or absent and usually infrequent, we extended the 
analysis to quantitative phenotypes related to hemostasis (e.g., factor VIII 
and prothrombin levels), which are measured on a continuous scale and 
probably closer connected to direct gene action. In Chapter II.1 the results are 
presented of an initial study, in which evidence was sought for a genetic basis 
for the variation in the plasma concentrations of several hemostatic measures. 
Chapter II.2 shows the results of a linkage analysis performed to identify 
loci influencing protein C activity as measured by concentrations of activated 
protein C in complex with two of its inhibitors α1-antitrypsin and protein C 
inhibitor, which showed high heritability in Chapter II.1. 
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Chapter I.1 
C.Y. Vossen, J. Conard, J. Fontcuberta, M. Makris, F.J.M. van der Meer, 
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Summary
We started a large multicenter prospective follow-up study to provide reliable 
risk estimates of venous thrombosis in families with various thrombophilic 
defects. This paper describes data collected at study entry on venous events 
experienced before study inclusion, i.e. the baseline data. All individuals 
(probands, relatives) registered in nine European thrombosis centers, with the 
factor V Leiden mutation, a deficiency of antithrombin, protein C or protein 
S, or a combination of these defects, were enrolled between March 1994 and 
September 1997. As control individuals, partners, friends or acquaintances of 
the thrombophilic participants were included. Incidence and relative risk of 
objectively confirmed venous thrombotic events (VTEs) prior to entry were 
calculated for the relatives with thrombophilia and the controls. Of the 846 
relatives with thrombophilia (excluding probands), 139 (16%) had experienced 
a VTE with an incidence of 4.4 per 1000 person years. Of the controls, 
15 of the 1212 (1%) controls had experienced a VTE with an incidence of 
0.3 per 1000 person years. The risk of venous thrombosis associated with 
familial thrombophilia was 15.7 (95% CI 9.2-26.8) and remained similar after 
adjustment for regional and sex-effects (16.4; 95% CI 9.6-28.0). The highest 
incidence per 1000 person years was found in relatives with combined defects 
(8.4; 95% CI 5.6-12.2), and the lowest incidence was found in those with 
the factor V Leiden mutation (1.5; 95% CI 0.8-2.6). Considerable differences 
in the lifetime risk of VTE were observed among individuals with different 
thrombophilia defects. 
Introduction
In developed countries, venous thrombosis occurs in 1 to 2 per 1000 
individuals per year1,2 and commonly manifests as deep vein thrombosis 
(DVT), with or without pulmonary embolism (PE).3 Major complications in the 
clinical course of DVT are death from PE, development of a disabling post-
thrombotic syndrome and recurrences.2,4-6 Predisposing factors for venous 
thrombosis can be genetic or acquired, or both, and may lead to a life-long 
or temporary increase in the tendency to venous thrombosis (thrombophilia).7 
As the clinical expression varies between individuals who are heterozygous for 
the same genetic thrombotic defect, as shown within genotypically identical 
family members8, venous thrombosis is believed to be a multicausal disease.9,10 
The hypothesis of multicausal pathogenesis is underlined by the finding that 
the risk of venous thrombosis is higher in families with inherited thrombophilia 
than in individuals with the same defect without a positive family history.11,12 
This difference probably is the result of interaction within these families of 
the inherited defect with other genetic or acquired risk factors.11-13 Several 
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hereditary prothrombotic defects have been identified in the last four decades. 
The first was antithrombin deficiency, identified in 1965.14 Since then, several 
other hereditary defects have been identified as risk factors for venous 
thrombosis, such as protein C deficiency, protein S deficiency, factor V Leiden 
and prothrombin G20210A.15-18   
Rational guidelines for optimal treatment policies in families with inherited 
thrombophilia are lacking due to few available studies of sufficient size. 
Therefore, we started a large multicenter prospective follow-up study to 
determine the natural history of venous thrombosis in family members of 
symptomatic patients with at least one inherited prothrombotic defect. 
With these risk estimates guidelines may be inferred for treatment and 
prevention of venous thrombosis in families with different kinds of inherited 
thrombophilia. Other endpoints such as arterial thrombotic disease (myocardial 
infarction, stroke), death from various causes, major hemorrhage and fetal 
loss were also studied. The European Prospective Cohort on Thrombophilia 
(EPCOT) study combines data on individuals with familial thrombophilia over a 
large geographical area of eight European nations and therefore is the largest 
cohort of individuals with inherited thrombophilia, thus providing reliable risk 
estimates.
This paper will describe the data collected at study entry on the occurrence of 
venous thrombosis in the EPCOT participants prior to entry, i.e. the baseline 
data on the history of venous thrombosis. 
Study design
Participants and methods
A total of nine centers (Barcelona, Bologna, Frankfurt, Glasgow, Leiden, 
Malmö, Paris, Sheffield and Vienna) with long-standing interest in 
thrombophilia research from eight countries participated in the EPCOT study. 
We included patients referred to these specialist clinics to create a large 
cohort of individuals with deficiencies in natural anticoagulants, which are 
rare, and to address the risk of venous thrombosis found in thrombophilic 
families compared with patients with a similar thrombophilia defect without a 
family history. Each center enrolled all registered probands (first of a family in 
whom thrombophilia was detected) with a deficiency of antithrombin, protein 
C or protein S, or factor V Leiden, who had at least one relative with the same 
familial defect, and their registered relatives. Fewer individuals with factor V 
Leiden were included than would be expected based on the frequency of this 
mutation; however, the factor V Leiden mutation was identified more recently 
than the other defects, of which carriers were collected over the past 15 
years. As controls, partners or, if there were none, friends or acquaintances 
of the thrombophilic participants were included. Controls were excluded if 
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they were known to have heritable thrombophilia or if they were related to 
a participant with an inherited thrombotic defect. There were no exclusion 
criteria for individuals with inherited thrombophilia: we included those who 
were symptomatic as well as those who were asymptomatic, and those who 
received anticoagulant treatment as well as those who did not. The study was 
approved by the Leiden University Hospital Medical Ethics Committee, and all 
participants in this study gave their informed consent.
Data collection
Inclusion took place between March 1994 and September 1997 with most 
of the participants (84% of controls and 88% of thrombophilic individuals) 
included in 1994 and 1995. Information was collected at inclusion, and 
annually during the prospective follow-up by standardized data collection 
forms. All data were collected by the responsible physician or another health 
professional at the participating centers by consulting another physician, 
by medical chart review or by telephone or mail contact with the patient. 
Completed forms were sent to the coordinating center with only the patient 
identifiers code to protect patient confidentiality. Data collected at study entry 
included information on general demographics, defect details (type, subtype, 
diagnostic methods, genetic confirmation), personal history with regard to 
thrombosis (dates, location, diagnostic test results), current medication (oral 
anticoagulants, oral contraceptives, hormone replacement therapy or other 
medication), other risk factors (e.g., obesity, varicose veins), obstetric history 
and family history of thrombosis. Data collection was identical for controls 
and thrombophilic individuals, except for items on the type and subtype of 
thrombophilia. 
All centers performed the various assays according to their local protocol 
and participated in an external quality assessment scheme for thrombophilia 
testing. For the first two years this was the quality assurance scheme 
developed for the European Concerted Action on Thrombosis (ECAT/EQAS) 
(Leiden, The Netherlands) and for the subsequent years, the UK NEQAS 
quality assurance scheme (Sheffield, UK). Diagnostic criteria were based on 
those used in these centers, which for the deficiencies was based on repeated 
testing, and in some cases also on genotypic confirmation. 
Recruitment was before identification of the G20210A mutation in the 
prothrombin gene. During prospective follow-up, we gathered information 
on the presence of this mutation as a second defect for 504 relatives and 
424 probands. Thus we only have information on the prothrombin G20210A 
mutation as a second defect in 64% of the participants with inherited 
thrombophilia.
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Analysis and statistics
For the analysis of the baseline data collected at study inclusion on the history 
of venous thrombotic events prior to study entry, we included only probands 
and relatives from families in which thrombophilia testing was done because 
of the occurrence of venous thrombosis in the proband or family, and not 
when this was done solely for research purposes or family planning. This 
restriction was to avoid selection bias and to stay as close as possible to the 
real-life situation of an individual from a symptomatic thrombophilia family 
asking a physician for advice. 
We were interested in the number, type, age at onset, event-free survival, 
incidence and relative risk of venous thromboembolic events (VTEs) 
experienced before inclusion in the study. Only objectively confirmed events 
(by ultrasound, Duplex or venography for DVT, and by ventilation-perfusion 
scanning or angiography for PE) and confirmed events at other locations were 
counted as such; non-definite events, i.e. based on clinical or patient diagnosis 
were recorded but not considered in the analysis reported here, including 
superficial thrombophlebitis. Spontaneous venous thrombosis was defined 
as venous thrombosis without known precipitating risk factors (hospital 
admission, surgery, immobilization, plaster cast, uninterrupted travels over 8 
hours, pregnancy, delivery). Thrombotic events in which the only risk factor 
was use of oral contraceptives were also labeled as spontaneous. 
As probands were selected on having had venous thrombosis, we determined 
only the number and type of events, the age of onset and the age at which 
50% of the probands had experienced venous thrombosis (median survival) 
prior to study entry. The probability of being free of events at any given age 
was analyzed by constructing Kaplan-Meier life tables. From these survival 
analyses we estimated the cumulative incidence of thrombosis with confidence 
intervals at age 30, 45 and 60. 
The incidence of venous thrombotic events in relatives and controls was 
calculated by dividing the number of events by the total of observation years, 
i.e. the time between birth and the first event of interest, or until the end 
of study, i.e. the inclusion in the EPCOT study without a history of DVT, PE 
or other major event. The 95% confidence intervals (CIs) were calculated 
according to a Poisson distribution for the number of events.19 Hazard ratios 
as an estimation of the relative risk were calculated by Cox-regression, with 
thrombosis as the dependent variable and presence of thrombophilia as an 
independent variable. Center (as stratum) and sex (as categorical variable) 
were entered in the Cox-regression model to adjust for regional and sex 
effects. Event-free survival, incidence and hazard ratios were calculated 
regardless of previous manifestations of superficial thrombophlebitis.
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Results
A total of 2838 participants were enrolled in the cohort of whom 1626 had a 
thrombophilic defect (672 probands, 954 relatives of probands) and 1212 were 
controls (900 partners, 312 friends). In total, 600 probands and 846 relatives 
met the criteria that they were initially investigated because of thrombosis 
themselves or because of thrombosis in a family member. 
The main characteristics at inclusion of probands, relatives and controls are 
depicted in Table 1. Among individuals with thrombophilia, men were slightly 
underrepresented (40% in probands and relatives). At study entry, 19 (10%) 
of the protein C deficient relatives, 43 (22%) of the protein S deficiency 
relatives, 32 (22%) of the antithrombin deficient relatives, 11 (5%) of the 
relatives with factor V Leiden and 22 (23%) of the relatives with combined 
defects received life-long anticoagulation.  
Thrombotic history
Probands Of all included probands, 532 (89%) had experienced an 
objectively confirmed venous thrombosis prior to study entry (Table 2). The 
remaining 68 probands (11%) had been identified because of superficial 
thrombophlebitis (n=58), or were the first in the family in whom a defect was 
demonstrated with no personal but only a family history of venous thrombosis 
(n=10). Of all probands with a personal history of thrombosis, 288 (54%) had 
experienced one or more recurrencies before study entry. The mean age at 
the first venous thrombosis was 30 years (range 0-71) and ranged per type 
of defect from 26 years in patients with antithrombin deficiency to 33 years in 
patients with protein C deficiency or factor V Leiden (Table 2). Of all probands, 
50% had experienced venous thrombosis before the age of 29 (Figure 1). 
Spontaneous venous thrombotic events, i.e. venous events without known 
precipitating risk factors or during use of oral contraceptives only, occurred in 
220 of the 362 (61%) probands for whom this information was available. 
Relatives and controls Of all included relatives, 139 (16%) had experienced 
an objectively confirmed venous thrombosis compared with 15 (1%) in the 
controls (Table 2) prior to study entry. The percentage of relatives with a 
venous event varied per type of defect from 6% in those with the factor 
V Leiden mutation to 29% in individuals with combined defects (Table 3). 
Recurrencies were present before baseline in 58 (42%) relatives with a history 
of venous thrombosis, and in only 2 (13%) of the controls with a history of 
venous thrombosis.
The mean age at the first venous thrombosis before study entry was 36 
years (range 13-71) in the relatives and 41 years (range 24-68) in the 
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Probands Relatives Controls
All (n) 600 846 1212
Men (n) 237 339 627
Women (n) 363 507 585
PC deficiency (n) 126a 188 N/a
PS deficiency (n) 93 193 N/a
AT deficiency (n)* 102 145 N/a
FVL (n) 175b 225c N/a
Combined defects (n) 104 95 N/a
    PC deficiency-PS deficiency (n) 2 2 N/a
    FVL-PC deficiency (n) 22d 22 N/a
    FVL-PS deficiency (n) 23d 24 N/a
    FVL-AT deficiency (n) 11 9 N/a
    PT20210A-PC deficiency (n) 11 12 N/a
    PT20210A-PS deficiency (n) 8 6e N/a
    PT20210A-AT deficiency (n) 5 6 N/a
    PT20210A-FVL (n) 19f 13g N/a
    PT20210A-FVL-PC deficiency (n) 2 1 N/a
    PT20210A-FVL-PS deficiency (n) 1 0 N/a
Age at inclusion (mean (range)) 41 (2-78) 39 (0-91) 42 (3-87)
    <18 yrs old (n) 5 73 36
   18-45 yrs old (n) 355 470 695
    >45 yrs old (n) 240 303 481
Table 1 General characteristics of the probands, relatives and controls at 
baseline
Abbrevations: PC=protein C, PS=protein S, AT=antithrombin, FVL=factor V Leiden, PT20210A= prothrombin 
G20210A, N/A=not applicable. a2 were homozygous b31 were homozygous c13 were homozygous
d1 was homozygous for FVL e1 was homozygous for PT20210A f4 were homozygous for FVL g1 was 
homozygous for FVL and 1 was homozygous for PT20210A *Six probands and 14 relatives showed only low 
antithrombin activity, 2 relatives were identified by DNA-testing only, and 5 probands and 7 relatives had only 
activity levels measured.
controls (Table 2). Per type of defect, the age of onset ranged from 28 years 
in relatives with combined defects to 42 years in relatives with protein C 
deficiency (Table 2).
Spontaneous venous events occurred before study entry in 54 of the 90 (60%) 
relatives and in 7 of the 14 (50%) controls for whom this information was 
available, with thrombotic events occurring during use of oral contraceptives 
considered as spontaneous events. 
The incidence of venous events experienced before study entry in relatives 
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Table 2 Description of objectively confirmed venous events before study entry
Thrombophilic individuals
Probands 
(n=600)
Relatives 
(n=846)
Controls 
(n=1212)
Individuals with venous events before baseline (n) 532 139 15
  DVT (n) 359 89 9
  PE (n) 154 45 3
  Other VT (n) 19 5 3
     PC deficiency (n) 110 22 N/a
     PS deficiency (n) 84 50 N/a
     AT deficiency (n) 90 25 N/a
     FVL (n) 152a 14b N/a
     Combined defects (n) 96c 28 N/a
Age at onset all major events (mean (range)) 30 (0-71) 36 (13-71) 41 (24-68)
     PC deficiency 32 (11-71) 42 (23-71) N/a
     PS deficiency 29 (2-68) 37 (13-71) N/a
     AT deficiency 26 (0-53) 34 (17-64) N/a
     FVL 33 (14-68) 38 (17-61) N/a
     Combined defects 28 (3-69) 28 (13-59) N/a
Abbreviations: DVT= deep venous thrombosis, PE= pulmonary embolism with or without DVT, VT= venous 
thrombosis, PC=protein C, PS=protein S, AT=antithrombin, FVL=factor V Leiden, N/a=not applicable. a30 
were homozygous b2 were homozygous c6 were homozygous for FVL
Figure 1 Venous event-free survival of the probands (solid line), relatives 
(short dashed line) and controls (long dashed line) until study entry
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Table 3 Incidence per 1000 person years of venous events before study entry in the 
controls and the relatives
All
(n) 
Events
(n (%))
Person years 
(yrs)
Incidence 
(per 1000 yrs (95% CI))
Controls 1212 15 (1) 51079 0.3 (0.2-0.5)
Men 627 9 (1) 26746 0.3 (0.2-0.6)
Women 585 6 (1) 24333 0.2 (0.1-0.5)
Age at inclusion >18 years* 1171 15 (1) 29504 0.5 (0.3-0.8)
Age at inclusion >45 years** 477 6 (1) 5712 1.1 (0.4-2.3)
Relatives 846 139 (16) 31660 4.4 (3.7-5.2)
PC deficiency 188 22 (12) 7059 3.1 (2.0-4.7)
PS deficiency 193 50 (26) 7059 7.1 (5.3-9.3)
AT deficiency 145 25 (17) 5034 5.0 (3.2-7.3)
FVL 225 14 (6) 9186 1.5 (0.8-2.6)
Combined defects 95 28 (29) 3322 8.4 (5.6-12.2)
Men 339 78 (23) 12634 6.2 (4.9-7.7)
Women 507 61 (12) 19026 3.2 (2.5-4.1)
Age at inclusion >18 years* 743 126 (17) 16893 7.5 (6.2-8.9)
Age at inclusion >45 years** 260 39 (15) 3593 10.9 (7.7-14.8)
Abbreviations: PC=protein C, PS=protein S, AT=antithrombin, FVL=Factor V Leiden, CI=confidence interval. 
*Only person years above 18 years were counted. Individuals older than 18 years at baseline who had 
events before age 18 were excluded. **Only person years above 45 years were counted. Individuals older 
than 45 years at baseline who had events before age 45 were excluded.
was 4.4 (95% CI 3.7-5.2) per 1000 person years and in controls 0.3 (95% 
CI 0.2-0.5) per 1000 person years (Table 3). Per type of thrombophilia, the 
incidence was lowest in the relatives with the factor V Leiden mutation (1.5 
per 1000 person years) and highest for those with combined defects (8.4 
per 1000 person years) (Table 3). The incidence regarding factor V Leiden 
did not change after exclusion of homozygous individuals. The incidence was 
higher in men in the relatives (6.2 per 1000 person years for men and 3.2 per 
1000 person years for women), but similar for both men and women in the 
controls (0.3 per 1000 person years for men and 0.2 per 1000 person years 
for women) (Table 3). 
The probability of being free of venous events before study entry in the 
thrombophilic individuals (probands excluded) was 91% (95% CI 89-93%) 
at age 30, 82% (95% CI 79-86%) at age 45 and 70% (95% CI 65-76%) at 
age 60 (Figure 1). Per type of defect, the probability of being free of venous 
events at age 45 was 87% with protein C deficiency, 74% with protein S 
deficiency, 80% with antithrombin deficiency, 94% with factor V Leiden and 
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67% with combined defects. In the controls, the probability of being free of 
venous thrombosis at age 30, 45 and 60 was, respectively, 100%, 99% (95% 
CI 98-100%) and 98% (95% CI 97-99%) (Figure 1). 
The risk of venous thrombosis derived from the incidences of venous events 
experienced before study entry was 16 times higher in the relatives with 
thrombophilia compared with the controls (relative risk of 15.7; 95% CI 9.2-
26.8) and remained similar after adjustment for center and sex (relative risk 
of 16.4; 95% CI 9.6-28.0) (Table 4). Per type of thrombophilia the relative 
risk differed greatly: the highest risk was found in the relatives with combined 
defects. For the relatives with single defects, the risk was highest in relatives 
with protein S deficiency (32.4; 95% CI 16.7-62.9) and lowest in the relatives 
with the factor V Leiden mutation (4.3; 95% CI 1.9-9.7) (Table 4). Exclusion of 
homozygous individuals with the factor V Leiden mutation did not affect these 
estimates. The relative risk was higher in men than in women: 18.1 (95% CI 
9.0-36.3) and 13.9 (95% CI 6.0-32.4), respectively (Table 4). 
Discussion
To obtain reliable estimates of the risk of venous thrombosis associated with 
familial thrombophilia caused by various defects, we started a prospective 
collaborative multinational study, including 1626 individuals with inherited 
thrombophilia and 1212 controls from eight European countries.  
Table 4 Relative risk of venous events before study entry in the relatives
Crude relative risk* Adjusted** relative risk
All relatives versus controls 15.7 (9.2-26.8) 16.4 (9.6-28.0)
PC deficiency 11.1 (5.7-21.4) 11.3 (5.7-22.3)
PS deficiency 26.1 (14.7-46.5) 32.4 (16.7-62.9)
AT deficiency 19.0 (10.0-36.1) 17.5 (9.1-33.8)
FVL 5.2 (2.5-10.8) 4.3 (1.9-9.7)
Combined defects 32.0 (17.1-60.0) 46.7 (22.5-97.1)
Men 19.2 (9.6-38.4) 18.1 (9.0-36.3)
Women 13.8 (5.9-31.8) 13.9 (6.0-32.4)
Age at inclusion >18 years# 14.4 (8.4-24.6) 14.4 (8.4-24.6)
Age at inclusion >45 years## 10.2 (4.3-24.0) 10.3 (4.3-24.4)
Abbreviations: PC=protein C, PS=protein S, AT=antithrombin, FVL=Factor V Leiden. *For every defect, we 
compared relatives with the defect with all controls. **Adjusted for regional and sex-effects. For the relative 
risk per sex, the relative risk was only adjusted for regional effects. #Only person years above 18 years 
were counted. Individuals older than 18 years at baseline who had events before age 18 were excluded. 
##Only person years above 45 years were counted. Individuals older than 45 years at baseline who had 
events before age 45 were excluded.
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Data collected at study entry on the history of venous thrombosis prior to 
study inclusion showed a 16 times increased risk of venous thromboembolic 
events for the individuals with inherited thrombophilia (only relatives of 
probands included) compared with the normal population (crude relative risk 
of 15.7 (95% CI 9.2-26.0), adjusted relative risk of 16.4 (95% CI 9.6-28.0) 
adjusted for sex and regional effects). The incidence of venous events before 
study entry was 4.4 per 1000 person years in the relatives, compared with 0.3 
per 1000 person years in the controls. 
The highest incidence of events and the lowest age at onset before study 
entry were found in the relatives with combined defects (8.4 per 1000 person 
years; mean age at onset 28 years), as has been described by other authors. 
11,20-25 For single defects we found the highest risk with protein S deficiency 
(7.1 per 1000 person years), and the lowest for factor V Leiden (1.5 per 1000 
person years). Although there is one report that protein S deficiency confers 
the highest risk of venous thromboembolism26, several others have shown 
that the greatest venous thromboembolic risk is associated with antithrombin 
deficiency.23,24,27,28 Whether there are real differences in the venous thrombotic 
risk in respect of antithrombin and protein S deficiency remains unresolved. 
The absence of a difference in our study might reflect differences in the 
distribution of, yet unknown, interacting second defects or the presence of 
the prothrombin G20210A mutation for which 36% of the participants could 
not be tested. It is, however, noteworthy, that a population study, in which 
selection or referral bias was excluded, also did not find a higher risk for 
antithrombin deficiency.29 Another possible explanation for these conflicting 
results is that since antithrombin deficiency was the first thrombophilia to 
be discovered, affected individuals could have received prophylaxis more 
frequently than individuals with other types of thrombophilia. However, when 
the year of diagnosis of thrombophilia was taken as follow-up endpoint instead 
of the age at which individuals were without venous events at study entry, the 
incidence was only slightly higher for individuals with antithrombin deficiency: 
5.9 per 1000 person years (95% CI 3.8-8.7).
The annual risk of thrombophilia-associated venous thrombosis before study 
entry was sex-dependent: the incidence was higher in male relatives, but 
similar for both male and female controls. As many venous thrombotic events 
in young women can be attributed to oral contraception, the low percentage 
of asymptomatic thrombophilic women using oral contraceptives (16%; age 
15-35) compared with asymptomatic female controls (37%; age 15-35) offers 
a likely explanation for a lower risk in women with thrombophilia compared 
with control women. Another explanation is that female relatives were 
referred to a thrombosis clinic for investigation before hormone prescription or 
pregnancy, whereas men were only referred when they were symptomatic. 
Labelling events as provoked or unprovoked is difficult and mostly dependent 
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on the researcher’s definition of a provoked event, e.g., we labeled events 
occuring during oral contraceptive use as unprovoked, as oral contraceptive 
use is a generally weak and very common risk factor during which 
anticoagulation treatment is mostly not considered. Studies including detailed, 
reliable information on risk factors could give insight in the risk of venous 
thrombosis associated with these risk factors.
We have included over 1500 individuals with familial thrombophilia from eight 
European countries, so our study yields reliable and generalizable results. It 
should be noted, however, that in this study follow-up was counted only for 
those entered in the cohort, i.e., individuals with any of these defects who 
died before the start of the study were not included. This implies that we may 
have underestimated the risk of thrombosis. However, in previous studies 
we have shown that the mortality of antithrombin deficiency30, protein C 
deficiency31 and factor V leiden32 does not exceed the population risk. We also 
only counted objectively confirmed manifestations of venous thrombosis to 
avoid selection bias, which means that we may have excluded inadequately 
diagnosed or missed events, and thus could have underestimated the risk. 
However, only a fraction of all reported events were not objectively confirmed. 
We also did not have full details on thromboprophylaxis prior to recruitment. 
The incidence of venous thromboembolic events may thus have been reduced 
in the relatives if short-term thromboprophylaxis was used to cover surgery, 
trauma or pregnancy. After diagnosis of a hereditary thrombotic defect, 
thromboprophylaxis may be more likely to be offered even to asymptomatic 
relatives and oral contraception with estrogen-containing preparations is 
discouraged at least in some countries. However, incidences per defect were 
only slightly higher or remained similar to the incidences shown in Table 3 
when the year of diagnosis of thrombophilia was taken as the study end-
point instead of the age at which individuals were without venous events at 
study entry. The risk of venous thrombosis might have been overestimated 
when mostly symptomatic relatives were referred to a thrombosis clinic for 
investigation. In addition, the risk for individuals with single defects might 
have been overestimated when they were carriers of the prothrombin 
G20210A mutation but could not be tested for this particular mutation in our 
study. 
It is important to note that our results concern individuals from thrombophilic 
families registered at specialized clinics, and hence the results may be 
generalized to such individuals, but not to unselected individuals with the 
same defect, as we have previously shown that these individuals have a lower 
risk of thrombosis.11,12
While more detailed data will result from the prospective follow-up, this 
study showed that individuals with familial thrombophilia have an increased 
risk of venous thrombosis with a high risk of spontaneous thrombosis and 
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recurrencies. Since 70% of the individuals with thrombophilic defects were 
free of thrombosis at age 60, it is unlikely that long-term anticoagulation 
started at a young age would have benefits outweighing the risks of this 
treatment especially in those with a single genetic prothrombotic defect.
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Summary
Reliable risk estimates for venous thrombosis in families with inherited 
thrombophilia are scarce but necessary for determining optimal screening 
and treatment policies. In the present analysis, we determined the risk of 
a first venous thrombotic event in carriers of a thrombophilic defect (i.e. 
antithrombin-, protein C- or protein S deficiency, or factor V Leiden). The 
asymptomatic carriers had been tested prior to this study in 9 European 
thrombosis centers because of a symptomatic carrier in the family, and 
were followed prospectively for 5.7 years on average between March 1994 
and January 2001. Annually, data were recorded on the occurrence of risk 
situations for venous thrombosis and events (e.g., venous thrombosis, death). 
Twenty-six of the 575 asymptomatic carriers (4.5%) and 7 of the 1118 
controls (0.6%) experienced a first deep venous thrombosis or pulmonary 
embolism during follow-up. Of these events, 58% occurred spontaneously in 
the carriers compared with 43% in the controls. The incidence of first events 
was 0.8% per year (95% CI 0.5-1.2) in the carriers compared with 0.1% per 
year (95% CI 0.0-0.2) in the controls. The highest incidence was associated 
with antithrombin deficiency or combined defects, and the lowest incidence 
with factor V Leiden. The incidence of venous events in asymptomatic 
individuals from thrombophilic families does not exceed the risk of bleeding 
associated with long-term anticoagulant treatment in the literature (1-3%). 
Introduction
Venous thrombosis has an overall incidence of about 1-2 per 1000 individuals 
per year and is a serious disorder with potential major complications such 
as death from pulmonary embolism, recurrences and the development of 
a disabling post-thrombotic syndrome1-3. It has been postulated that not a 
single risk factor, but interaction between multiple genetic and environmental 
risk factors is a prerequisite for venous thrombosis to develop4-6. Currently, 
several genetic risk factors are known to increase the risk of venous 
thrombosis: deficiencies in the anticoagulation factors protein C, protein S and 
antithrombin, and the factor V Leiden and prothrombin G20210A mutations 
7-11. In accordance with the multicausal nature of thrombosis, it was found 
that the presence of a family history of venous thrombosis increases the 
thrombotic risk in individuals with protein C deficiency or factor V Leiden, most 
likely due to the concomitant presence of other genetic or environmental risk 
factors within the family6,12,13.
A prerequisite to determining the optimal clinical approach, e.g., with 
regard to screening or (long-term) prophylactic anticoagulant treatment in 
families with inherited thrombophilia is to define the absolute risk of venous 
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thrombosis, and to weigh this risk against the risk of bleeding complications 
associated with prophylactic treatment. To obtain valid risk estimates of the 
absolute risk of venous thrombosis in families with inherited thrombophilia, 
we started the European Prospective Cohort on Thrombophilia (EPCOT) 
study. The EPCOT study, by combining data from nine centers, is the largest 
prospective cohort of individuals with deficiencies of protein C, protein S 
and antithrombin, and factor V Leiden. In this paper, we present data on 
the risk of a first venous thromboembolic event associated with inherited 
thrombophilia in relatives of probands from thrombophilic families who were 
asymptomatic at the time of inclusion in the study. 
Methods
Participants
The design of the study has been described in detail previously14. In short, 
inclusion of the participants took place between March 1994 and September 
1997 with prospective follow-up until January 2001. Nine centers from eight 
countries (Austria, France, Germany, Italy, Spain, Sweden, The Netherlands 
and the United Kingdom) participated. Each center enrolled all registered 
probands (first of a family in whom thrombophilia was detected) with a 
deficiency of protein C, protein S or antithrombin, or factor V Leiden, and their 
registered relatives with one of these defects. Healthy partners, or, if there 
were none, friends or acquaintances of participating individuals with inherited 
thrombophilia were included as controls. Controls were excluded if they were 
known to have heritable thrombophilia, or if they were related to a participant 
with an inherited thrombotic defect. Controls were, however, not tested 
for any of the defects under study after study entry. All participants gave 
informed consent. Data were collected at baseline, and annually during follow-
up. At study entry data were collected on subjects’ general demographics, 
hereditary defect (type, subtype (if available), levels (if available), information 
on DNA testing), current medication and current risk factors for thrombosis, 
history of thrombosis, obstetric history and family history of thrombosis. The 
data recorded at follow-up included the occurrence of risk situations (surgery, 
hospital admission, plaster casts, prolonged bed rest (>2 weeks), traveling 
(>8 hours), details on pregnancies, medication) and on outcome events (e.g., 
venous thrombosis, hemorrhage, death). Completed forms were sent to the 
coordinating center with only the patient identifiers code to protect patient 
confidentiality.
From a total of 1626 individuals with thrombophilic defects and 1212 control 
subjects, this paper includes only relatives of probands who had not previously 
experienced any venous thrombotic event (deep venous thrombosis (DVT), 
pulmonary embolism (PE), or superficial thrombophlebitis (STP)) before 
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inclusion in the study, and who did not receive long-term prophylactic oral 
anticoagulant treatment during prospective follow-up (defined as treatment 
for at least 1 year without interruptions). Twenty thrombophilic individuals 
received long-term prophylactic oral anticoagulant treatment: 10 for 
prevention of venous thrombosis and 10 for a personal history of arterial 
disease. Eight controls received long-term anticoagulation treatment for 
an arterial indication. In addition, we only included relatives of probands 
tested because of venous thrombosis or a positive family history. Families 
in which thrombophilia was detected because of screening before hormone 
prescription or research purposes were not included, in an effort to stay as 
close as possible to the real-life situation of an individual from a symptomatic 
thrombophilia family asking a physician for advice. 
Recruitment was before description of the G20210A mutation in the 
prothrombin gene, but during prospective follow-up we gathered information 
on the presence of this mutation as an additional defect.
Quality assessment thrombophilia testing and verification of events
The participating centers performed the various assays according to their 
local protocol and participated in an external quality assessment scheme for 
thrombophilia testing. For the first two years this was the quality assurance 
scheme developed for the European Concerted Action on Thrombosis (ECAT/
EQAS) (Leiden) and for the subsequent years the UK National External Quality 
Assessment Service (NEQAS) (Sheffield, UK). 
Per center, a local investigator verified all events in prospective follow-up. In 
case of death, the autopsy data were collected, if available. An adjudication 
committee scored all reported events independently after receiving all the 
relevant medical information from each center, but in case of doubt or when 
no consensus was reached at first, further information was asked for (e.g., 
actual test results). Committee members were not blinded for whether a 
person was a thrombophilia carrier or control, but were unaware of the 
type of defect of the carriers. Venous thromboses were classified as definite 
venous events when they were objectively confirmed, i.e. for DVT by 
ultrasound (duplex, Doppler), impedance plethysmography, venography or 
leg symptoms plus definite PE, and for PE by angiography, high probability 
ventilation-perfusion-scan, spiral computerized tomography or autopsy. STPs 
were considered definite events when diagnosed by a physician. For the 
analysis reported here, we included only definite venous events. Consensus 
on the classification of the venous events, i.e. that a majority of the steering 
committee members agreed, was reached in 67 of the 72 (93%) reported 
events during prospective follow-up (47 DVTs or PEs, 21 STPs, 4 major 
hemorrhages). Of the remaining 5 events, which were classified as definite 
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DVT or PE (n=4) or no PE (n=1), consensus was reached after additional 
information was provided (n=4) or after reconsideration (n=1). For controls, 
immediate consensus was reached in 88% of the reported events (15 out of 
17) and in thrombophilic subjects in 95% of the reported events (52 out of 
55).
Analysis and statistics
We calculated the annual absolute risk (incidence) and relative risk of a 
first DVT or PE for various groups in the cohort. The incidence of venous 
thrombotic events was calculated by dividing the number of events by the 
total of observation-years (follow-up time). Follow-up time was the time 
between inclusion and the event of interest, death or the last date of follow-
up (the end of the study or last date before loss-to-follow-up), whichever 
occurred first. A DVT or PE was considered first event only when not 
preceded by a STP. If a PE followed a DVT within 3 months, these events 
were considered a single event. The 95% confidence intervals (95% CIs) 
were calculated according to a Poisson distribution for the number of events 
15. Hazard ratios as estimation of the relative risk of venous thrombosis were 
calculated by Cox-regression with venous thrombosis as the dependent 
variable and presence or absence of thrombophilia as independent variable. 
Center, age (as stratum: age <45 or ≥45), and sex were entered in the Cox-
regression model to adjust for center, age and sex effects. 
Results
We collected prospective data on 575 relatives with a thrombophilic defect 
and 1118 controls (825 partners, 293 friends), all without a thrombotic event 
prior to inclusion and not on long-term oral anticoagulant treatment. The total 
follow-up time was 3283 years in the individuals with thrombophilia (mean 
5.7; range 0.2-7.3) and 6289 years in the controls (mean 5.6; range 0.7-
7.2). During follow-up, 20 thrombophilic subjects and 64 controls were lost 
to follow-up (complete follow-up in 95%), and 8 thrombophilic individuals 
and 12 controls died. The causes of death in the carriers were heart disease 
(n=3), suspected pulmonary embolism (n=1), and other causes (n=4). 
Causes of death in controls were not related to venous thrombosis (cancer 
(n=4), myocardial infarction (n=4), accidents in traffic or at work (n=3), or 
surgery (n=1)). The main characteristics at inclusion are shown in Table 1. A 
preponderance of the thrombophilic individuals was female (62%), whereas 
sex was distributed more equally distributed among the controls. 
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Table 1 General characteristics at inclusion
Thrombophilic 
individuals 
Controls
All (n) 575 1118
  Men (n) 214 588
  Women (n) 361 530
     OCC use, age 10-50 (n/total n)* 63/265 153/360
     HRT use, age ≥50 (n/total n) 17/77 47/159
  PC deficiency (n) 143 N/a
  PS deficiency (n) 107 N/a
  AT deficiency (n) 96 N/a
  FVL (n) 173a N/a
  Combined defects (n) 56 N/a
     PC-PS (n) 1 N/a
     FVL-PC (n) 11 N/a
     FVL-PS (n) 15 N/a
     FVL-AT (n) 6 N/a
     FVL-PT20210A (n) 8b N/a
     PT20210A-PC (n) 9 N/a
     PT20210A-PS (n) 4c N/a
     PT20210A-AT (n) 2 N/a
Mean age at inclusion (years (range)) 35 (0-91) 41(3-87)
Mean BMI (kg/m2 (range))** 23 (13-42) 24 (13-39)
Cancer ever (n (%)) 8 (1) 12 (1)
Abbreviations: OCC=oral contraceptives, HRT=hormone replacement therapy, PC=protein C, PS=protein 
S, AT=antithrombin, FVL= factor V Leiden, PT20210A=prothrombin G20210A, N/a=not applicable, BMI= 
body mass index. a10 were homozygous b1 was homozygous for factor V Leiden c1 was homozygous for 
prothrombin G20210A *The oral contraceptives contained estrogen in 34/265 (13%) thrombophilic women, 
and 139/360 (39%) of the control women. **Information on BMI was available for 574 thrombophilic 
individuals and 1117 controls. 
Risk of a first event 
Of the 575 thrombophilic individuals, 26 thrombophilic subjects experienced 
a first DVT or PE during follow-up (4.5%) (1 relative had a mesenteric vein 
thrombosis) compared with 7 of the 1118 controls (0.6%) (Table 2). The 
events occurred spontaneously, i.e. did not occur after exposure to a known 
acquired risk factor, in 15 thrombophilic individuals (58%) and 3 controls 
(43%). The risk factors present at the time of the event in the remaining 11 
thrombophilic individuals were hospitalization (n=3), hormone replacement 
therapy (n=2), infection (n=2), pregnancy (n=2), cancer (n=1) and oral 
contraceptives (n=1), and in the 4 remaining controls surgery (n=2), 
hospitalization (n=1) and cancer (n=1). The incidence of a first DVT or PE was 
higher in the thrombophilic individuals than in the controls, respectively, 0.8% 
per year (95% CI 0.5-1.2) compared with 0.1% per year (95% CI 0.0-0.2) 
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(Table 2) with a relative risk of 9.0 (95% CI 3.8-21.1), adjusted for sex, age 
at entry and center effects (crude relative risk: 7.3; 95% CI 3.2-16.8). The 
incidence of a STP as first event was 0.5% per year (95% CI 0.3-0.8) in the 
thrombophilic subjects, and 0.1% per year (95% CI 0.0-0.2) in the controls 
(Table 2) with a relative risk of 5.2 (95% CI 2.0-13.7), adjusted for sex, age at 
entry and center effects (crude relative risk: 5.3; 95% CI 2.1-13.5). 
The annual incidence of a first DVT or PE was highest for thrombophilic 
individuals with antithrombin deficiency (1.7%/year; 95% CI 0.8-3.3) or 
combined defects (1.6%/year; 95% CI 0.5-3.7) and lowest in thrombophilic 
individuals with the factor V Leiden mutation (0.1%/year; 95% CI 0.0-0.6) 
(Table 2). Unfortunately, the numbers per type of defect were too small 
to estimate the risks by age and sex. Our database contained subtype 
information (or sufficient level information to determine the subtype) of 120 
protein C deficient individuals, 97 individuals with protein S deficiency and 76 
individuals with antithrombin deficiency. When we included in the analysis only 
individuals known to have subtype I (103 with protein C deficiency, 68 with 
protein S deficiency, and 59 with antithrombin deficiency), the risk of a major 
event was similar to the risk in Table 2. The risk of thrombosis in those with 
a type II defect or type III protein S defect was not lower than in those with 
type I abnormalities, although the number of individuals (n=63) with type II 
or III defects was low (results not shown). 
In men with thrombophilia, the annual incidence of a first DVT or PE was 
higher (1.4%/year; 95% CI 0.8-2.2) compared with thrombophilic women 
(0.5%/year; 95% CI 0.2-0.9) (Table 2). In controls, the incidences of a first 
DVT or PE did not differ between the sexes (Table 2). The percentage of 
women above the age of 50 using hormone replacement therapy was slightly 
lower in thrombophilic women (22%) compared with controls (30%), whereas 
a much lower percentage of women with inherited thrombophilia used 
estrogen-containing oral contraceptives (13%; age 10-50 years) compared 
with the control women (39%; age 10-50 years). The incidence of a first DVT 
or PE in thrombophilic women who did not use oral contraceptives (age 10-50 
years) was 0.4%/year (95% CI 0.1-0.9) compared with 0.5%/year (95% CI 
0.0-2.9) in women using estrogen-containing oral contraceptives. 
The first DVT or PE occurred about 20 years earlier in the thrombophilic 
individuals than in the controls (Table 2). The mean age at onset was ~40 
years for individuals with protein C-, protein S- or antithrombin deficiency or 
combined defects and 63 years for those with factor V Leiden in comparison to 
63 years in the controls (Table 2). 
The risk of a first DVT or PE was 1.0% per year (95% CI 0.6-1.6) among the 
285 thrombophilic individuals who encountered acquired risk factors during 
prospective follow-up and who did not receive short-term anticoagulation 
during these risk situations (i.e. surgery, hospitalization, bed rest for more 
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than 13 days, plaster cast, cancer, pregnancy or traveling for more than 8 
hours). Table 3 shows the frequency of venous events associated with the 
presence of acquired risk factors during prospective follow-up for which 
no short-term prophylactic anticoagulant treatment was provided. Cancer, 
although the number of individuals was small, and pregnancy appear to 
be the risk factors during which most secondary venous events occurred in 
the thrombophilic individuals. The incidence of a first DVT or PE in the 156 
thrombophilic individuals who did not encounter acquired risk factors for which 
they could have received short-term anticoagulation during prospective follow-
up was, however, similar: 0.8% per year (95% CI 0.3-1.7).
A total of 134 thrombophilic individuals (23%) received short-term 
prophylactic anticoagulation during one or more risk situations: surgery 
(n=95), pregnancy (n=43; 13 during puerperium only; range start treatment 
during pregnancy: week 5-week 36), plaster cast (n=13), traveling (n=9) and 
after twisting a knee or an ankle (n=2). No venous events occurred during any 
Table 2 Incidence (%/year) and age at onset of a first venous thrombosis 
Total 
subjects
DVT/PE
n n Age onset, 
years 
(range)
Person 
years,
n
Incidence, 
%/year 
(95% CI)
Thrombophilic individuals 575 26 40 (20-65) 3194.4 0.8 (0.5-1.2)
Protein C deficiency 143 6 41(22-65) 833.2 0.7 (0.3-1.6)
Protein S deficiency 107 5 38 (28-63) 619.1 0.8 (0.3-1.9)
Antithrombin deficiency 96 9 39 (21-58) 520.6 1.7 (0.8-3.3)
Factor V Leiden 173 1* 63 902.1 0.1 (0.0-0.6)
Multiple defects 56 5* 36 (20-62) 319.4 1.6 (0.5-3.7)
Males 214 16 37 (20-65) 1162.0 1.4 (0.8-2.2)
Females 361 10 44 (21-65) 2032.4 0.5 (0.2-0.9)
Age at inclusion 18-45 yrs 339 18 32 (21-47) 1880.1 1.0 (0.6-1.5)
Age at inclusion above 45 yrs 146 7 61 (51-65) 793.2 0.9 (0.4-1.8)
Controls 1118 7 63 (38-84) 6269.6 0.1 (0.0-0.2)
Males 588 2 58 (57-59) 3303.0 0.1 (0.0-0.2)
Females 530 5 64 (38-84) 2966.6 0.2 (0.1-0.4)
Age at inclusion 18-45 yrs 652 1 38 3601.8 0.0 (0.0-0.2)
Age at inclusion above 45 yrs 426 6 67 (57-84) 2445.7 0.2 (0.1-0.5)
Abbreviations: DVT=deep venous thrombosis, PE=pulmonary embolism, CI=confidence interval
*All were heterozygous.
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of these risk situations under short-term prophylactic anticoagulant treatment. 
Of the controls, 115 (10%) also received short-term anticoagulant treatment 
during risk situations: during surgery (n=107), pregnancy (n=4; 3 during 
puerperium only), plaster cast (n=12), traveling (n=1) and after twisting a 
knee (n=1) or during chronic enteritis (n=1). 
Table 3 Number of first venous events per risk situation for which subjects did not 
receive short-term prophylactic anticoagulation
Thrombophilic individuals Controls
n Situations, 
n
DVT/PE,
n (%)
n Situations, 
n
DVT/PE,
n (%)
Travel (>8 hours) 260 504* 0 (0%) 567 1244* 0 (0%)
Surgery/immobilization** 143 176 3 (2%) 290 407 2 (0%)
Plaster cast 27 33 0 (0%) 59 71 0 (0%)
Cancer# 10 10 1 (10%) 17 17 1 (6%)
Pregnancies 24 28 2 (7%) 61 75 0 (0%)
Abbreviations: DVT=deep venous thrombosis, PE=pulmonary embolism. *The number of follow-up years 
in which individuals reported to have traveled at least once for more than 8 hours. **Immobilization is 
defined as a hospital stay, or bed rest for at least 14 days at home. #Defined as malignancy still present 
or developed during prospective follow-up. Nine (4 thrombophilic individuals, 5 controls) received 
anticoagulation during and after surgery for cancer. 
Discussion
We conducted a large prospective follow-up study in nine centers in eight 
countries on 1626 probands and relatives, and 1212 controls to obtain 
valid estimates of the risk of venous thrombosis in families with inherited 
thrombophilia. In the present report, we describe the risk of a first venous 
thromboembolic event in 575 thrombophilic individuals and 1118 control 
subjects who were followed up to 7 years (mean follow-up 5.6 years) and who 
were asymptomatic and not on long-term anticoagulant treatment at study 
inclusion. 
Among the thrombophilic individuals, the annual risk of a first DVT or PE 
was 0.8% per year. The incidence was lowest for thrombophilic individuals 
with factor V Leiden (0.1%/year) and highest for thrombophilic subjects 
with antithrombin deficiency (1.7%/year), individuals with combined defects 
(1.6%/year) and men (1.4%/year). DVTs and PEs occurred spontaneously in 
58% of the thrombophilic individuals and 43% of the controls. The annual risk 
was not increased in thrombophilic individuals who encountered additional 
acquired risk situations (e.g., surgery, immobilization, pregnancy, plaster cast) 
during which no short-term anticoagulation treatment was prescribed. As 
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134 thrombophilic individuals did receive short-term anticoagulation during 
risk situations, mainly during pregnancy and surgery, this finding could be 
the result of the intention of doctors to treat those with a high risk of venous 
thrombosis only in definite high-risk situations.
The strongest point of this study is its size: deficiencies of natural 
anticoagulants are rare, and large prospective studies are therefore scarce. 
We excluded events that were not objectively confirmed; as these were few 
and equally distributed over thrombophilic individuals and controls (of the 
DVTs and PEs 12% were non-definite in the carriers compared with 14% in 
the controls) this could not have affected our results. The results of this study 
should not be generalized to all individuals with thrombophilia, as we focused 
on asymptomatic subjects with familial thrombophilia, to which patient group 
these results apply. We have shown previously that the risk of thrombosis is 
higher in selected individuals from families with a clear familial thrombophilia, 
than in unselected individuals without a strong family history, regardless of 
the defect12,13. Other studies on the risk of a first venous thrombotic event 
in carriers of a hereditary defect16-22 reported annual incidences of venous 
thrombosis ranging from 0.4% to 2.5% for protein C deficiency, 0.1% to 3.2% 
for protein S deficiency, and 0.9% to 2.9% for antithrombin deficiency. For 
factor V Leiden, the reported incidences ranged from 0.1% to 0.7% per year 
17,19,23-25. The risks found in the present study could have been underestimated 
due to preventative measures taken by the treating physicians, who were 
aware of the presence of a thrombophilic defect, to reduce the risk of venous 
thrombosis. However, the risk for individuals with single defects might have 
been overestimated when they carried the prothrombin G20210A mutation 
but were not tested for this particular mutation in our study. We were able to 
gather information on the presence of this mutation as an additional defect for 
360 of the 575 thrombophilic individuals (63%).
Although the risk of a first DVT or PE was increased in thrombophilic 
individuals, the risk was still quite low and did not outweigh the reported 
risk of 1-3% of hemorrhagic complications in patients with prolonged 
anticoagulant therapy with target INRs with a lower limit of 2.026,27. Therefore, 
long-term prophylactic anticoagulant treatment does not seem beneficial in 
asymptomatic relatives of symptomatic probands with inherited thrombophilia, 
although future prophylactic treatment options with a lower risk of bleeding 
might change this. However, there might be a need for a more stringent 
thromboprophylactic treatment policy during temporary periods of increased 
thrombotic risk as no DVT or PE occurred in thrombophilic individuals 
during risk situations in which prophylactic anticoagulation was used. In the 
thrombophilic individuals, 42% of all DVTs or PEs occurred in the presence of 
a known risk situation and could therefore have been prevented. 
Whether screening or short-term prophylaxis would be beneficial is difficult to 
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conclude from our results, as the low risk of thrombosis might be the result 
of screening and a policy aimed at preventing thrombosis, as can be deduced 
from the low number of women with estrogen-containing oral contraceptives 
and the high number of women with prophylactic anticoagulant therapy during 
pregnancy or puerperium. Further studies should elucidate whether a more 
stringent policy of thromboprophylaxis in risk situations could further reduce 
the risk of thrombosis, which should in particular focus on individuals with 
antithrombin deficiency and combined defects, who had the highest risk of 
thrombosis. 
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Summary
Few comprehensive data are available on the recurrence rate of venous 
thrombosis in carriers of thrombophilic defects from thrombophilic families. 
We prospectively determined the recurrence rate after a first venous 
thrombotic event in patients with familial thrombophilia due to factor V Leiden 
or deficiencies of protein C, S or antithrombin. Data were gathered during 
follow-up on the occurrence of risk situations, anticoagulation treatment 
and events (e.g., venous thrombosis, hemorrhage). Over a mean follow-up 
period of 5.6 years, 44 of the 180 (24%) patients with familial thrombophilia 
who did not use long-term anticoagulation experienced a recurrent venous 
thromboembolic event (5.0%/year; 95% CI 3.6-6.7) compared with 7 of 
the 124 patients (6%) on long-term anticoagulation (1.1%/year; 95% CI 
0.4-2.2). Spontaneous events occurred less often in patients on long-term 
anticoagulation (57%) than in patients without long-term anticoagulation 
(75%). The highest recurrence rate was found among men and women 
with antithrombin deficiency. Although long-term anticoagulation treatment 
decreased the incidence of recurrent events with 80%, it also resulted in a risk 
of major hemorrhage of 0.8% per year. A positive benefit-risk ratio of long-
term anticoagulation after a first event is most likely present in patients with 
familial antithrombin deficiency.
Introduction
A prior history of venous thrombosis is a strong predictor for venous 
thrombosis, with recurrences in 6-13% of consecutive patients after 1 year 
and 13-28% after 5 years.1-5 Patients with a first venous thrombotic event will 
receive oral anticoagulant treatment for at least 3 months after a deep vein 
thrombosis and at least 6 months after a pulmonary embolism. Decisions on 
extending anticoagulant treatment are based on the individual’s respective 
risks of venous thromboembolism recurrence and anticoagulant-related 
bleeding. Whether long-term continuation of anticoagulant treatment should 
be considered after a first venous event in carriers of a thrombophilic defect 
from thrombophilic families is still uncertain, as few comprehensive data are 
available on whether inherited risk factors increase the risk of recurrence. 
As was shown by us previously, it might be important to distinguish between 
unselected patients with a thrombophilic defect and individuals from 
thrombophilic families, as the latter tend to have a much higher risk at onset 
of disease due to the concomitant presence of other risk factors within these 
families.6,7 To our knowledge, only two studies described the recurrence risk 
associated with familial deficiencies of protein C, protein S and antithrombin: 
Pabinger et al. found a high recurrence rate of 63% for patients with 
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familial deficiencies of natural anticoagulant factors8, and annual incidences 
calculated on available literature by Van den Belt et al. ranged from 13 to 
17% for patients with familial antithrombin deficiency and from 14 to 16% 
for patients with familial protein S deficiency.9 In the same paper by Van den 
Belt et al., the results of a retrospective cohort study revealed a cumulative 
incidence of 10% after 1 year and 23% after 5 years for patients with 
inherited antithrombin-, protein S- or protein C deficiency.9 For factor V Leiden 
contradicting results have been published about the risk of recurrent venous 
thrombosis10-14, but only one study focused on patients with a positive family 
history and concluded that the incidence of recurrent venous events depends 
on the presence of other thrombophilic disorders.15 
We started the European Prospective Cohort on Thrombophilia (EPCOT) study, 
a large prospective cohort study of individuals with familial thrombophilia, 
to obtain reliable risk estimates of the absolute risk of venous thrombosis in 
families with inherited thrombophilia. The aim of the current analysis was to 
determine the recurrence risk for participants with a hereditary thrombophilic 
defect and a history of one venous thromboembolic event before study 
entry. We focused on selected families with a clear thrombotic tendency, and 
the results could assist physicians in decisions on testing on thrombophilic 
abnormalities and choices about long-term anticoagulation after a first 
thrombosis.
Methods
Participants
The design of the study has been described in detail previously.16 In brief, all 
EPCOT participants were included between March 1994 and September 1997. 
Follow-up was until January 2001. Nine centers from eight European countries 
(Austria, France, Germany, Great Britain, Italy, The Netherlands, Spain, 
and Sweden) with expertise on thrombophilia research enrolled registered 
individuals: both probands (the first of a family identified with thrombophilia) 
and their registered relatives with inherited thrombophilia. The defects of 
interest were deficiencies of antithrombin, protein C, protein S or factor V 
Leiden. Recruitment was before description of the prothrombin G20210A 
polymorphism. During prospective follow-up, we gathered information on 
the presence of the prothrombin G20210A polymorphism as a second defect 
for 207 of the 304 patients (68%) with one venous thromboembolic event 
at inclusion. Data recorded by the responsible physician or other health 
professional during follow-up included the occurrence of acquired risk 
situations (surgery, hospital admission, plaster cast, prolonged bed rest (for 
more than 2 weeks), traveling (for more than 8 hours), pregnancy, use of 
female hormones), and anticoagulation treatment and event details (e.g., 
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venous thrombosis, hemorrhage, death). All participants in this study gave 
informed consent. 
From all 1626 thrombophilic participants included in the study at baseline, this 
paper includes only those who had had one objectively confirmed deep venous 
thrombosis (DVT) or pulmonary embolism (PE)), or a DVT and PE as single 
event before inclusion in the EPCOT study. Thus, all individuals who were 
asymptomatic at entry or had suffered more than one thrombosis before study 
entry were excluded. We also did not include families in which thrombophilia 
was detected because of screening before hormone prescription or research 
purposes to stay as close as possible to the real-life situation of an individual 
from a symptomatic thrombophilia family asking a physician for advice. 
We distinguished two treatment groups: thrombophilic patients who did, and 
those who did not receive long-term prophylactic anticoagulant treatment 
during prospective follow-up. Long-term anticoagulation was defined as 
prophylactic treatment for at least one year or throughout the total follow-up 
period if the follow-up time was less than one year. Thrombophilic individuals 
who received anticoagulation treatment for more than 1 year after a non-
confirmed DVT, PE or superficial thrombophlebitis were also considered to 
have received long-term anticoagulation. The decision to prescribe long-
term treatment was left to the treating physician, and based on various local 
policies and individual considerations.
Quality assessment of thrombophilia testing and verification of events
All centers performed the various assays according to their local protocol 
and participated in an external quality assessment scheme for thrombophilia 
testing (ECAT/UK NEQAS). An adjudication committee, who received all the 
relevant medical information, scored all reported venous thromboembolic 
events and hemorrhages independently. Venous thromboembolic events were 
classified as definite when they were objectively confirmed, i.e. for DVT by 
ultrasound, impedance plethysmography, venography, or leg symptoms plus a 
definite PE, and for a PE by angiography, high probability ventilation-perfusion-
scan, spiral computerized tomography or autopsy. Superficial venous events 
were considered definite events when diagnosed by a physician (and not 
only by the patient). Hemorrhages were classified into severe hemorrhages 
(requiring hospital admission for emergency diagnosis or treatment), life-
threatening hemorrhages (leading to either surgery, irreversible functional 
damage, or two out of the following three symptoms; severe blood loss, 
hypotension (systolic blood pressure<90 mm Hg) and anemia (<4mmol/l 
hemoglobin)), and fatal hemorrhages (rapidly leading to death). Adjudication 
committee members (FRR, IDW, JF, FEP) agreed on the classification of 
events in 83 of the 86 (97%) venous thrombotic events and 10 of the 12 
(83%) severe hemorrhages experienced by the thrombophilic patients during 
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prospective follow-up. Only definite events were included in the analysis 
reported here. A DVT or PE was considered a first event regardless of previous 
superficial thrombophlebitis and was considered a single event when both DVT 
and PE were diagnosed within 3 months. 
Spontaneous venous thromboembolic events were defined as venous 
thrombosis without known precipitating risk factors (hospital admission, 
surgery, immobilization, plaster cast, uninterrupted travels over 8 hours, 
pregnancy, delivery). Events that had occurred before study entry during the 
use of female hormones were labeled as unprovoked due to a lack of detailed 
information.16 However, during prospective follow-up, we did label events 
during use of female hormones as provoked. 
Analysis and statistics 
For all symptomatic patients, we calculated the absolute risk (incidence) 
of recurrent venous thrombosis during follow-up by dividing the number of 
events by the total of observation-years (follow-up time). Follow-up time was 
defined as the time between inclusion and the event of interest, death, or 
the last date of follow-up (the end of the study or last date before loss-to-
follow-up), whichever occurred first. In addition, we calculated the incidence 
of severe hemorrhage among patients on long-term anticoagulation. We 
calculated the incidences for the group without long-term anticoagulation 
on an intention-to-treat basis, thus follow-up time was not corrected for the 
time individuals did or did not receive short-term treatment. For those on 
long-term anticoagulation, follow-up time was defined as the time between 
the start of anticoagulation treatment and the event of interest, death, the 
last date of anticoagulation treatment or the last date of follow-up, whichever 
occurred first. Calculation of the 95% confidence intervals was according to a 
Poisson distribution for the number of events.17 At study entry, we gathered 
information from all symptomatic carriers on the year (before study entry) in 
which their first venous event had occurred. The year of a first event ranged 
among the symptomatic patients from 1957 to 1995, therefore we calculated 
the recurrent event-free survival according to the number of observation years 
instead of the number of follow-up years using the Kurtzke method.18 This 
means that subjects who entered the study in 1995 and had their first event in 
1985 will only contribute to the survival curve from year 10 on. To determine 
the benefit of long-term anticoagulation, a hazard ratio as estimation of the 
relative risk of venous thrombosis was calculated by Cox-regression, with 
venous thrombosis as the outcome variable and treatment policy (long-term or 
not) as independent variable. Center, age (as stratum: age<45 and age>=45), 
and sex were entered in the Cox-regression model to adjust for regional, age 
and sex effects. 
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Results 
Prospective data were collected on 304 patients with a history of one 
objectively confirmed DVT or PE before inclusion in the follow-up study. Of 
these subjects, 124 patients (69 probands and 55 relatives) were classified as 
being on long-term anticoagulation during prospective follow-up, while 180 
patients (139 probands and 41 relatives) were not on long-term prophylactic 
anticoagulation. The total prospective follow-up time of the 304 patients was 
1710 years (mean 5.6; range 1-7 years). During follow-up, twelve patients 
were lost to follow-up and six patients died as a result of heart disease (n=2), 
cancer (n=2), septic shock (n=1) and pneumonia (n=1).
Table 1 depicts the main characteristics at inclusion of the patients. Among 
those not on long-term anticoagulation there were relatively fewer men and 
more probands than among those who received long-term anticoagulation. 
The latter can be explained by a low frequency of long-term anticoagulation 
among probands with factor V Leiden. 
Recurrence rates 
Of the 180 patients who did not receive long-term anticoagulant treatment 
during prospective follow-up, 44 (24%) experienced a recurrent thrombotic 
event (Table 2) compared with 7 of the 124 (6%) patients on long-term 
anticoagulant treatment (Table 3). Of the patients who did not receive long-
term anticoagulant treatment, 4 used aspirin and 2 used heparin (short-
term during surgery and pregnancy) at the time of the event. Thirty-three 
of the 44 events (75%) in those not on long-term anticoagulation occurred 
spontaneously, and the 11 remaining events occurred after traveling for more 
than 8 hours (n=5), during pregnancy (n=3), and after surgery (n=3). Of 
the patients on long-term anticoagulation, 4 of the 7 events (57%) occurred 
spontaneously: two events occurred during or after pregnancy, and one 
event occurred after strenuous exercise (karate). Thirteen of the 180 patients 
(7%) who did not use long-term anticoagulation experienced a superficial 
thrombophlebitic event during prospective follow-up (i.e. as the only venous 
recurrent event or before a recurrent DVT or PE) compared with 9 of the 124 
patients (7%) on long-term anticoagulation.
The recurrence rate was 5.0% per year (95% CI 3.6-6.7) in patients who 
were not on long-term anticoagulation and 1.1% per year (95% CI 0.4-2.2) 
in those on long-term anticoagulation (Tables 2 and 3). Thus, the risk of 
recurrent events was 80% lower in the patients on long-term anticoagulation 
treatment (crude relative risk 0.2; 95% CI 0.1-0.4; unchanged when adjusted 
for center, sex and age at inclusion). In patients who did not receive long-
term anticoagulation treatment, the recurrence rate was much higher among 
men (9.6%/year; 95% CI 6.3-13.9) than among women (2.8%/year; 95% CI 
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Table 1 General characteristics of the thrombophilic subjects with 1 confirmed DVT or 
PE at study entry
Patients (n=304)
No long-term 
anticoagulation
Long-term anticoagulation
All, n 180 124
Men, n (%) 63 (35) 59 (48)
Probands, n (%) 139 (77) 69 (56)
Age at inclusion, mean years (range) 39 (14-78) 41 (20-72)
Age at 1st event, mean years (range) 32 (11-70) 33 (13-71)
Type of thrombophilia
Protein C deficiency, n 37 32
Protein S deficiency, n 25 30
Antithrombin deficiency, n 11 26
Factor V Leiden, n 79 (12 AA) 13 (4 AA)
Combined defects, n 28 23
PC-PS   0   1
PC-FVL   6   7
PC-PT   3   4
PC-FVL-PT   2   0
PS-FVL   4   4
PS-PT   2   2
AT-FVL   2   3
AT-PT   2   1
FVL-PT   7   1#
Risk factors
BMI, mean kg/m2 (range) 25 (17-47) 25 (17-34)
Cancer ever, % 2 0
Arterial disease, % 3 9
Thrombosis history
DVT, n (%) 133 (74) 79 (64)
PE, n (%)* 47 (26) 45 (36)
Spontaneous DVT or PE, n (%)** 105 (58) 62 (50)
History of STPs, n (%) 37 (21) 40 (32)
Time between 1st event and study entry, 
mean years (range)
6.4 (0-38) 7.3 (0-33)
Abbreviations: PC=protein C deficiency, PS=protein S deficiency, AT=antithrombin deficiency, FVL= factor 
V Leiden, AA=homozygotes for factor V Leiden, PT=prothrombin G20210A, BMI= body mass index, 
DVT=deep venous thrombosis, PE=pulmonary embolism, STP=superficial thrombophlebitis. *A DVT and PE 
were experienced at the same time by 29 patients without and 29 patients with long-term anticoagulation. 
**Defined at entry as events in the absence of the following risk situations: surgery, cancer, hospitalization, 
plaster cast, immobilisation, pregnancy, and travelling. #One was homozygous for FVL.
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1.7-4.5) (Table 2) with a relative risk of 3.0 (95% CI 1.6-5.6), which remained 
unchanged when adjusted for age (relative risk 3.1; 95% CI 1.6-5.9) or when 
we restricted the analysis to those with a first spontaneous venous thrombotic 
event (relative risk 3.1; 95% CI 1.4-7.1). Amongst the thrombophilic women 
who were not on long-term anticoagulation, measures to reduce the risk 
of recurrence associated with pregnancy or use of female hormones were 
frequently employed: 25 of the 29 (86%) women who were pregnant during 
prospective follow-up received thromboprophylaxis during pregnancy or 
puerperium, and only 13 of the 100 (13%) women between the age of 15 and 
50 used oral contraceptives, of whom 9 women used oral contraceptives which 
contained no estrogen. Amongst the thrombophilic women who were on long-
term anticoagulation 10 of the 50 (20%) women between the age of 15 and 
50 used oral contraceptives, of whom 9 women used estrogen-containing oral 
contraceptives. 
The lowest recurrence rates, although the confidence intervals were wide, 
were found in patients with factor V Leiden (3.5%/year without and 0.0%/
year with long-term treatment), and the highest recurrence rates in patients 
with antithrombin deficiency (10.5%/year without and 2.7%/year with 
long-term treatment) (Tables 2 and 3). However, when we calculated the 
incidences for men and women separately, we found among those not on 
long-term anticoagulation high and similar recurrence rates for men with 
protein C, protein S or antithrombin deficiency and men with multiple defects 
(10.5-11.6%/year; Table 2). For men with factor V Leiden we found a lower 
rate (7.2%/year; Table 2). For women, except for those with antithrombin 
deficiency (9.5%/year), the recurrence rates were much lower (2.1-3.1%/
year; Table 2). Besides a difference in the recurrence rate among men and 
Table 3 Incidence rates (%/year) of a recurrent DVT and/or PE in patients on long-
term anticoagulant treatment during prospective follow-up
n Time between 1st 
event and study 
entry, mean 
years (range)
DVT/PE,
n
Person years 
(during treatment 
only), n
Incidence rate, 
%/year (95% CI)
All 124 7.5 (0-36) 7* 652.0 1.1 (0.4-2.2)
PC deficiency 32 6.7 (0-29) 1 172.1 0.6 (0.0-3.2)
PS deficiency 30 6.2 (0-20) 1 172.8 0.6 (0.0-3.2)
AT deficiency 26# 6.7 (0-26) 4 146.9 2.7 (0.7-7.0)
Factor V Leiden 13 7.3 (1-24) 0 43.4 0.0 (0.0-8.5)
Combined defects 23 11.2 (0-36) 1** 116.8 0.9 (0.0-4.8)
Abbreviations: DVT=deep venous thrombosis, PE=pulmonary embolism, PC=protein C, PS=protein S, 
AT=antithrombin, CI=confidence interval, N/a= not applicable. *Five patients experienced a DVT, 1 a PE 
and 1 a cerebral venous event. **This individual was protein S deficient and factor V Leiden carrier. #One 
individual received antithrombin concentrate as anticoagulation therapy.
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women who received no long-term anticoagulation, we found, although 
confidence intervals were wide, a higher recurrence rate in the probands, 
in the patients with a spontaneous first past event and in those with a 
concurrent DVT and PE as first event (Table 4). In patients on long-term 
anticoagulation, recurrence rates were independent of sex (recurrence rates 
of 1.0%/year for men and 1.2%/year for women), and the etiology of the 
first event (spontaneous or not) (Table 4). The influence of risk situations 
on the risk of venous thrombosis was difficult to determine as short-term 
prophylaxis was prescribed frequently in patients who were not on long-term 
anticoagulation: in 6 of the 11 individuals wearing a plaster cast, in 7 of the 
83 patients who traveled and in 29 of the 71 patients undergoing surgery or 
hospitalization. 
Table 4 Incidence rates (% per year) in subgroups
Incidence, % per year (95% CI) 
No long-term anticoagulation
(N=180)
Long-term anticoagulation*
(N=124)
Probands 5.6 (4.0-7.7) 1.4 (0.5-3.3)
Relatives 3.1 (1.3-6.5) 0.7 (0.1-2.4)
History spontaneous events 5.7 (3.8-8.2) 1.2 (0.3-3.2)
No history spontaneous events 4.0 (2.2-6.6) 0.9 (0.2-2.7)
History of concurrent DVT/PE 8.5 (4.4-14.8) 1.1 (0.1-4.1)
History of DVT or PE only 4.3 (3.0-6.1) 1.0 (0.3-2.4)
Abbreviations: CI=confidence interval, DVT=deep venous thrombosis, PE=pulmonary embolism.
* Incidence was in percentage per year on thromboprophylaxis
Figure 1 shows the recurrence-free survival curve according to the 
number of observation years. For the subjects who were not on long-term 
anticoagulation, five individuals were included in the same year as their 
first event occurred, and 28 individuals entered the study in 1994 or 1995 
and had experienced their first event in, respectively, 1993 or 1994. After 2 
years of observation, these 5 and 28 individuals were followed prospectively 
for, respectively, 2 years and 1 year, and 12% of these 33 individuals had 
experienced a recurrent event (Figure 1). After 5 years of observation, 
an additional 10% of the subjects had experienced an event (Figure 1). 
Recurrence-free survival was higher for subjects who were on long-term 
anticoagulation: after 2 years of observation, 7 and 11 individuals were 
followed prospectively for, respectively, 2 years and 1 year, and 6% of these 
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18 individuals had experienced a recurrent event (Figure 1). After 5 years of 
observation, no additional subjects had experienced an event (Figure 1).  
Risk from prophylactic anticoagulation
Two women who did not use long-term anticoagulation experienced a severe 
hemorrhage during delivery while receiving short-term heparin treatment to 
prevent thrombosis during pregnancy. Five patients experienced a severe 
hemorrhage during the use of long-term anticoagulation (3 gastro-intestinal 
hemorrhages and 2 post-operative bleeding episodes after a hysterectomy or a 
thrombectomy) requiring hospital admission for an emergency diagnosis or for 
treatment. One additional patient experienced a post-operative hemorrhage 
after the removal of a melanoma, but had stopped oral anticoagulation two 
weeks before during treatment with penicillin for erysipelas. The incidence of 
severe hemorrhages associated with the use of oral anticoagulation was 0.8% 
per year (95% CI 0.3-1.8; 5 events on 638 years of anticoagulation).
Figure 1 Percentage of individuals who were free of a recurrent venous event accord-
ing to the number of years after a first event (calculated using the Kurtzke method) 
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Discussion
The recurrence rate of venous thrombosis after a first DVT or PE was 5.0% 
per year (95% CI 3.6-6.7) in the 180 patients who did not receive long-term 
anticoagulation during prospective follow-up. In these patients, the recurrence 
rate of venous thrombosis was much higher in men than in women with a 
relative risk, adjusted for age, of 3.1 (95% CI 1.6-5.9), which is in accordance 
with a recent paper by Kyrle et al. who reported a relative risk of recurrence 
of 3.6 (95% CI 2.3-5.5) for men compared with women.19 However, it 
should be noted that measures to reduce the risk of recurrence associated 
with pregnancy or use of female hormones were frequently employed. The 
incidence was also higher for patients in whom the first event had been a 
spontaneous event, as previously reported by others.20-22 In addition, we 
found a higher recurrence rate in patients who had experienced a DVT and 
PE concurrently as a first event than in those with a DVT or PE as first event. 
For factor V Leiden carriers the recurrence rate (3.5% per year) was similar 
to the incidences found in several prospective and retrospective studies on 
unselected patients with factor V Leiden of about 5% per year.10-13 The risk 
of a recurrent event in unselected patients with a first thrombotic event is 
reported to be highest in the first year after a first event (6-13% after 1 year 
compared with 13-28% after 5 years).1-5 However, as most symptomatic 
individuals in the present study did not enter the study in the same year as 
they had experienced their first event, our rates are less comparable to the 
rates found in other studies. When we took the year of a first event into 
account, we found that 12% of the subjects who did not receive long-term 
anticoagulation had experienced a recurrent event after 2 years. After 5 
years of observation, an additional 10% had experienced a recurrent event. A 
discrepancy with earlier found rates1-5 could be explained by the fact that we 
only had information on the year of a first event and not the exact date, which 
might lead to under- or overestimation of the years between a first event and 
inclusion.
The recurrence rate was 80% lower in the patients using long-term 
anticoagulation treatment with an incidence of recurrent events of 1.1% per 
year (95% CI 0.4-2.2). De Stefano et al. found a low annual incidence of 
1.4% for individuals with antithrombin-, protein S- or protein C deficiency in a 
retrospective study in which most individuals received life-long prophylaxis.23 
Their finding is similar to the recurrence rate found in the present study for 
patients with protein C-, protein S- or antithrombin deficiency receiving long-
term anticoagulation (1.2%/year; 95% CI 0.4-2.7), although the recurrence 
rate for antithrombin deficiency remained high (2.7% per year). The reduction 
of the recurrence rate with 80% came with an increase in the risk of severe 
hemorrhages during use of long-term anticoagulation of 0.8% per year (95% 
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CI 0.3-1.8), which is similar to the incidence of major hemorrhages of 1-3% 
found in other studies.24,25
The strength of our study is its size due to the collaboration of several 
European thrombosis centers, which made the restriction to patients with 
one venous thrombotic event possible. However, the present study was an 
observational study, and it is possible that those on long-term anticoagulation 
were those with a high recurrence risk and that those not on long-term 
anticoagulation were those with a lower recurrence risk or a past history of 
(severe) hemorrhage: randomized studies will be required to demonstrate 
whether the difference in recurrence and bleeding risk brought about by long-
term treatment is indeed as we have found, although the low prevalence of 
some of the thrombophilic disorders may render this infeasible. Likewise, the 
availability of anticoagulants with a better risk-benefit profile could change 
the balance. In addition, this study focused on subjects already tested 
for inherited thrombophilia, and due to preventive strategies their risk of 
recurrence may have been lower than in untested patients; hence, we cannot 
fully infer the effects of testing for thrombophilic defects. We did not include 
individuals with a non-objectively confirmed recurrent venous event only; 
however, these were few (n=4). 
Generally, the recurrence rate in patients with familial thrombophilia was 
similar to the recurrence rate found in consecutive patients in the absence 
of long-term anticoagulation treatment. However, we found a much higher 
recurrence rate in men, and a high recurrence rate for patients, men and 
women, with antithrombin deficiency (over 10%/year). In the patients who 
received long-term anticoagulation, the recurrence rate was 80% lower, at 
an increased risk of severe hemorrhages. A positive benefit-risk ratio of long-
term anticoagulation after a first event is most likely present in patients with 
antithrombin deficiency, who still showed a recurrence rate of 2.7% on long-
term anticoagulation.
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Summary
As the placental vessels are dependent on the normal balance of procoagulant 
and anticoagulant mechanisms, inherited thrombophilia may be associated 
with fetal loss. We performed a prospective study to investigate the relation 
between inherited thrombophilia and fetal loss, and the influence of 
thromboprophylaxis on pregnancy outcome. Women were enrolled in the 
European Prospective Cohort on Thrombophilia (EPCOT). These included 
women with factor V Leiden or a deficiency of antithrombin, protein C 
or protein S. Controls were partners or acquaintances of thrombophilic 
individuals. A total of 191 women (131 with thrombophilia, 60 controls) had 
a pregnancy outcome during prospective follow-up. Risk of fetal loss and 
effect of thromboprophylaxis were estimated by frequency calculation and 
Cox-regression modelling. The risk of fetal loss appeared slightly increased in 
women with thrombophilia without a previous history of fetal loss who did not 
use any anticoagulants during pregnancy (7/39 versus 7/51; relative risk 1.4; 
95% CI 0.4-4.7). Per type of defect the relative risk varied only minimally from 
1.4 for factor V Leiden to 1.6 for antithrombin deficiency compared to control 
women. Prophylactic anticoagulant treatment during pregnancy in 83 women 
with thrombophilia differed greatly in type, dose and duration, precluding solid 
conclusions on the effect of thromboprophylaxis on fetal loss. No clear benefit 
of anticoagulant prophylaxis was apparent. Women with thrombophilia appear 
to have an increased risk of fetal loss, although the likelihood of a positive 
outcome is high in both women with thrombophilia and in controls. 
Introduction
Thrombotic risk is increased in normal pregnancy, which may be the result 
of an evolutionary advantage associated with reduced blood loss after 
delivery and placenta separation. This risk is further enhanced in women 
with congenital or acquired thrombophilia.1 In addition it has been shown 
that postpartum blood loss is reduced in women with factor V Leiden.2,3 As 
an adequate placental circulation is dependent on the normal balance of 
procoagulant and anticoagulant mechanisms, inherited thrombophilia may be 
associated with fetal loss. 
In a retrospective analysis4 of women participating in the European Prospective 
Cohort on Thrombophilia (EPCOT) study, we observed a slightly increased risk 
of fetal loss in women with hereditary thrombophilia (168/571 versus 93/395; 
odds ratio 1.35; 95% confidence interval (CI) 1.10-1.82). Several other studies 
have confirmed an association between thrombophilia and fetal loss.5-18
Subsequent to our retrospective baseline analysis4, we followed the women 
in the EPCOT cohort prospectively to investigate the relation between fetal 
66
I.4 Hereditary thrombophilia and fetal loss: a prospective follow-up study
67
I.4
loss and inherited thrombophilia. The prospective study design allowed 
us to study women in a well-defined and homogeneous time frame with 
homogeneous general conditions, as well as to reduce recall bias. To prevent 
venous thromboembolism during pregnancy, pregnant women with inherited 
thrombophilia often receive thromboprophylaxis, such as heparin, oral 
anticoagulants or aspirin. This policy is a matter of controversy, and therefore 
applied in some centers, but not in all. As thromboprophylaxis could prevent 
fetal loss by preventing thrombosis in fetal placental vessels, we evaluated the 
effect of anticoagulants during pregnancy on pregnancy outcome.
Subjects and methods
Subjects
The women described in this study were enrolled in the EPCOT study between 
March 1994 and September 1997 and subsequently followed prospectively. 
The primary aim of the EPCOT-study was to establish the risk of thrombosis in 
individuals with inherited thrombophilia. Nine centers in 8 countries (Austria, 
France, Germany, Great Britain, Italy, The Netherlands, Spain, and Sweden) 
participated and followed all consenting individuals with a deficiency of natural 
coagulation inhibitors (antithrombin, protein C, protein S), resistance to 
activated protein C due to factor V Leiden, or a combination of these defects. 
As controls, partners or, if there were none, friends or acquaintances of the 
thrombophilic participants were included. Data were collected at baseline, 
and annually at follow-up by questionnaire, telephone or personal interview 
until January 2001. For follow-up data, information on the occurrence of 
risk situations or events was screened by questionnaire or telephone, and, 
when reported, further information was obtained from a physician. The data 
recorded at baseline included general demographic information, history with 
regard to thrombosis, current medication, obstetric history, family information 
and (only for thrombophilic individuals) details on type and subtype of 
thrombophilia. The data recorded at follow-up included the number of 
births, pregnancies and miscarriages, current medication and occurrence 
of risk situations for thrombosis. While there were no exclusion criteria for 
thrombophilic individuals, controls were excluded when they were blood 
relatives of an individual with an inherited thrombotic defect or were known to 
have heritable thrombophilia. 
For assessing the risk of fetal loss, we selected from the participating women 
those aged between 13 and 45, with at least one pregnancy ending in livebirth 
or fetal loss during prospective follow-up. We excluded women with only 
elective pregnancy terminations. Partners of men in the cohort or female 
acquaintances of thrombophilic individuals were included as controls. 
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Analysis
Only the first pregnancy during prospective follow-up (regardless of previous 
pregnancies reported before inclusion) was considered for the analysis. Risk 
was expressed as the frequency of fetal loss, i.e., the proportion of all first 
pregnancies ending in fetal loss. Fetal loss was defined as any loss during 
pregnancy independent of time of occurrence.
In the analysis aimed at assessing the risk of fetal loss associated with 
thrombophilia, we excluded women who used thromboprophylaxis during their 
first pregnancy during prospective follow-up. The effect of anticoagulants on 
pregnancy outcome was analyzed by comparing the risk of fetal loss between 
those with anticoagulants (heparin, oral anticoagulants) during the first 
pregnancy and those without thromboprophylaxis during the first pregnancy 
since study entry. Both calculations were performed per pregnant woman (i.e., 
not per pregnancy) by Cox-regression analysis with fetal loss as the outcome 
(dependent) variable and presence of thrombophilia or use of prophylaxis 
as covariate (independent variable). Follow-up time was the number of 
weeks of pregnancy. To adjust for regional effects and the influence of the 
number of previous pregnancies, center (as stratum) and the total number 
of pregnancies (as independent variable) were added in the Cox regression 
model. We also considered the effect of a history of fetal loss or venous 
thrombosis and the influence of gestation at age 35 or older. 
Results
A total of 1573 women were enrolled in the cohort (988 with thrombophilia, 
585 controls), of whom 191 completed at least one pregnancy during 
prospective follow-up (131 with thrombophilia, 60 controls). Of the controls, 
37 (62%) were female partners and 23 (38%) were friends of participants 
with thrombophilia. Among the 131 thrombophilic women, 83 (63%) used 
thromboprophylaxis during the first pregnancy in prospective follow-up. 
None of the controls used thromboprophylaxis during pregnancy. The 
main characteristics are shown in Table 1. Most women had their first 
fetal loss during prospective follow-up. A history of venous thrombosis 
was present predominantly among women with thrombophilia who used 
thromboprophylaxis during the first pregnancy since study entry. 
Fetal loss 
A total of 108 women (48 with thrombophilia, 60 controls) did not use 
thromboprophylaxis during the first pregnancy since study entry. Fetal loss 
occurred among 10 of the 48 women with thrombophilia (21%), and among 
10 of the 60 control women (17%). The relative risk for fetal loss associated 
with thrombophilia was 1.4 (95% CI 0.5-3.8); adjusted for center and the 
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Table 1 Inclusion characteristics of women pregnant during prospective fol-
low-up
Women with thrombophilia (n=131)
First pregnancy after 
study entry without 
thromboprophylaxis 
 (n=48)
First pregnancy after 
study entry
with thromboprophylaxis
(n=83)
Controls (n=60)
Age at inclusion, mean (range) 28.7 (19-41) 29.1 (16-39) 28.7 (13-38)
History of pregnancies, n (%)* 30 (63%) 48 (58%) 34 (57%)
History of fetal loss, n (%)# 9 (19%) 12 (14%) 9 (15%)
History of VT, n (%) 9 (19%) 43 (52%) 0 (0%)
Abbreviation: VT=Venous thrombosis *Range of number of pregnancies was 1-7 in women with 
thrombophilia and 1-5 in controls. #All women had 1 previous fetal loss.
number of pregnancies. In both thrombophilic women and controls, the 
risk of fetal loss was higher if they had a history of fetal loss (3/9 (33%) in 
both women with thrombophilia and controls) or when women were ≥35 
years old or older at gestation (4/9 (44%) in women with thrombophilia, 3/9 
(33%) in controls) (Table 2). A history of venous thrombosis (only present 
in women with thrombophilia) did not affect the risk of fetal loss. Further 
adjustment for a history of fetal loss and age at gestation (<35 vs ≥35) 
resulted in a relative risk of 1.7 (95% CI 0.6-4.6) for thrombophilic women 
versus controls. Exclusion of women with a history of fetal loss resulted in a 
relative risk of 1.4 (95% CI 0.4-4.7) for thrombophilia carriers versus pregnant 
control women, adjusted for age at pregnancy, regional effects and number 
of total pregnancies. Per type of defect, the relative risk, adjusted for age 
at gestation and number of previous pregnancies, varied little: 1.4 (95% CI 
0.3-5.5) for the factor V Leiden mutation, 1.5 (95% CI 0.2-12.9) for protein 
S deficiency, 1.5 (95% CI 0.3-7.9) for protein C deficiency and 1.6 (0.3-14.0) 
for antithrombin deficiency. Of all thrombophilic women and controls with 
no previous pregnancies before prospective follow-up, 2 of the 18 (11%) 
thrombophilic women and 5 of the 26 (19%) controls experienced fetal loss. 
The mean number of weeks at which fetal loss took place was week 9 (range 
4-18) in women with thrombophilia and week 9 (range 4-17) in controls. Eight 
women with thrombophilia (80%) and nine controls (90%) experienced a 
first trimester fetal loss (between week 0 and 12) with a relative risk for first- 
trimester fetal losses of 1.6 (95% CI 0.5-4.7) adjusted for age at pregnancy, 
regional effects and number of total pregnancies. The frequency of caesarian 
sections was the same for women with thrombophilia (21%) and control 
women (20%). 
For 91 of the 131 pregnant women with thrombophilia, we had information 
on genotyping for the prothrombin G20210A mutation. None of the 12 women 
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I.4Table 2 Fetal loss in women without thromboprophylaxis (heparin, oral anticoagu-
lants, aspirin) during pregnancy
Women with thrombophilia Controls
Single defects Combined
defects
Total
PC PS AT FVL*
Pregnant, n 13 7 5 21 2# 48 60
Fetal loss, n 4 2 1 3 0 10 (21%) 10 (17%)
History of fetal loss, n 2 1 0 5 1 9 9
Fetal loss , n 2 1 0 0 0 3 (33%) 3 (33%)
Age at pregnancy ≥ 35, n 1 2 1 4 1 9 9
Fetal loss, n 1 1 0 2 0 4 (44%) 3 (33%)
Abbreviations: PC=Protein C deficiency, PS=protein S deficiency, AT=antithrombin deficiency, FVL= factor V 
Leiden mutation. *Only heterozygotes. #Both had protein S deficiency and the factor V Leiden mutation.
with this mutation (11 heterozygous, 1 homozygous) experienced fetal loss. 
So, among a total of 14 women with combined defects, no pregnancy loss was 
observed.
Most of the controls were partners of men with a thrombotic defect. We 
assessed the effect of paternal thrombophilia on pregnancy outcome, and 
found none: the relative risk of fetal loss for partner controls versus friend 
controls was 0.4 (95% CI 0.1-2.2), adjusted for center, age at gestation, 
number of pregnancies and history of fetal loss.
Effect of using anticoagulants
A total of 83 women with thrombophilia received thromboprophylaxis, 
i.e. heparin (n=77), oral anticoagulants (n=5) or aspirin (n=1), at some 
point during the first pregnancy in prospective follow-up. The frequency of 
thromboprophylaxis varied among centers between 31% and 93% of all 
pregnant women with thrombophilia. The percentage of women receiving 
thromboprophylaxis was high for women with antithrombin deficiency or 
combined defects, respectively 82% and 83%, compared with 61% of the 
women with protein C deficiency, 70% of the women with protein S deficiency 
and 42% of the women with the factor V Leiden mutation. The indication for 
thromboprophylactic treatment during pregnancy was known for 71 women 
(86%), of whom only 20 women (28%) received thromboprophylaxis to 
prevent fetal loss. The type, dose and duration of anticoagulant treatment 
therefore ranged greatly among the women with thrombophilia. Among 21 
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women with thrombophilia who used heparin or oral anticoagulants before 
week 5 of the pregnancy until the end of the pregnancy, 5 (24%) experienced 
fetal loss with an unadjusted relative risk of fetal loss associated with 
thromboprophylaxis of 1.1 (95% CI 0.4-3.3), and a relative risk adjusted for 
center, total number of pregnancies, history of fetal loss and age at gestation 
of 0.7 (95% CI 0.2-3.2). The mean pregnancy duration until miscarriage in 
these women was 13 weeks (range 6-29). 
Discussion 
Earlier retrospective data in the EPCOT study showed that the risk of fetal loss 
was increased in women with thrombophilia (168/571 versus 93/395; odds 
ratio 1.35; 95% CI 1.01-1.82).4 We found a similar risk during this prospective 
follow-up study of 1.4 (95% CI 0.4-4.7) for thrombophilic women without a 
previous history of fetal loss and who did not use any anticoagulants during 
pregnancy versus controls, adjusted for age, number of previous pregnancies 
and regional effects. Even though the present study in itself could not exclude 
the absence of an increased risk with a 95% confidence interval from 0.4 to 
4.7, this statistical uncertainty is likely to be the result of the smaller number 
of pregnancies compared with the retrospective analysis and the results of 
both analyses are in agreement. A major difference between the prospective 
and retrospective analysis is that the odds ratio in the retrospective analysis 
was higher for stillbirth than for miscarriage, whereas none of the women 
experienced a stillbirth in the prospective analysis. This difference is probably 
the result of the lower number of individuals followed in the prospective 
study; 4% of the thrombophilic women experienced a stillbirth in the 
retrospective study and 27% a miscarriage, so if we take these percentages 
(which are based on a longer follow-up period), we would expect 2 stillbirths 
and 13 miscarriages in the 48 women without use of anticoagulants during 
prospective follow-up. 
Per defect, we found similar risks of fetal loss: 1.4 (95% CI 0.3-5.5) for the 
factor V Leiden mutation, 1.5 (95% CI 0.2-12.9) for protein S deficiency, 1.5 
(95% CI 0.3-7.9) for protein C deficiency and 1.6 (0.3-14.0) for antithrombin 
deficiency. Previously, we found similar odds ratios for miscarriage per type of 
defect: 0.9 (95% CI 0.5-1.5) for the factor V Leiden mutation, 1.2 (95% CI 
0.7-1.9) for protein S deficiency, 1.4 (95% CI 0.9-2.2) for protein C deficiency 
and 1.7 (95% CI 1.0-2.8) for antithrombin deficiency.4
Earlier retrospective studies reported similar19,20 or higher10,15 risks of fetal 
loss in women with a deficiency of antithrombin, protein S or protein C. For 
factor V Leiden, several previous reports showed an association with late fetal 
loss (2nd and 3rd trimester)5,6,8-11,16-18, while reports were contradictory on the 
association with early fetal loss (1st trimester).5,7,9,12-14,16-18,21-24 Discrepancies 
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between studies could be explained by their design: many previous reports 
were based on case-control studies targeting recurrent miscarriage without 
a comparison with women in the general population, which precludes risk 
calculation. According to Bick et al, 55 to 62% of recurrent miscarriages 
are caused by blood coagulation protein or platelet defects, whereas about 
90% of first time miscarriages are caused by chromosomal defects.25 In our 
study most women (39/48 (81%); Table 1) had their first fetal loss during 
prospective follow-up. It may well be that thrombophilia plays a role in a small 
selected group of women with recurrent fetal loss, who are likely to have 
other, some as yet unknown, defects. 
We found no positive effect of thromboprophylaxis on the outcome of 
a pregnancy in 21 women with thrombophilia who used heparin or oral 
anticoagulants before week 5 of the pregnancy until the end of the pregnancy 
(relative risk 0.7; 95% CI 0.2-3.2). However, this group is rather small to 
draw solid conclusions from and treatment in this group differed per person 
in type and dose as most women received thromboprophylactic treatment 
during pregnancy to prevent venous thrombosis. However, since the risk of 
fetal loss without thromboprophylaxis was only mildly increased, a strong 
beneficial effect could not be expected in this study. In women with a severe 
thrombotic tendency and recurrent fetal loss, thromboprophylaxis may offer 
more benefit, although currently only non-conclusive information is available 
on thromboprophylaxis for pregnant women with thrombophilia and a history 
of obstetric complications.9,26-29 
In conclusion, although the risk of fetal loss is increased in women with 
thrombophilia, the overall likelihood of a positive outcome is high. Further 
research regarding prophylactic treatment (heparin, oral anticoagulants 
or newly developed anticoagulants) should be performed, targetting high-
risk women, weighing risks and benefit. At the moment, thrombophylactic 
treatment does not seem indicated in women without a history of fetal loss 
for prevention of fetal loss only, while it may be a worthwhile option in women 
with a severe thrombotic tendency and recurrent fetal loss.  
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Abstract
Previously, we observed a positive association of prothrombin concentrations 
with thrombin generation (fragment 1+2) and thrombin activity (fibrinopeptide 
A), but no association with protein C activation peptide levels. We further 
evaluated a potential beneficial effect of increased prothrombin concentrations 
on activated protein C generation by assessing the plasma concentration 
of activated protein C in complex with protein C inhibitor (APC-PCI). Blood 
samples were used from 195 family members of a large French-Canadian 
kindred with type I protein C deficiency due to a 3363C insertion in the 
protein C gene. We utilized a new and highly sensitive assay for measuring 
the concentration of APC-PCI complex as a measure of the level of activation 
of protein C. Means of the plasma concentrations of APC-PCI complex were 
compared among carriers and non-carriers of the prothrombin G20210A 
mutation. Protein C activity levels were positively associated with APC-PCI 
complex plasma concentrations; however, APC-PCI complex levels were not 
different for carriers of the prothrombin G20210A mutation than for non-
carriers. Thus, carriers of the prothrombin G20210A mutation do not have 
increased protein C activation despite the increased thrombin generation 
resulting from the higher prothrombin concentrations associated with the 
G20210A mutation.  
Introduction
Protein C is a vitamin K dependent (molecular weight 62 000) zymogen for 
a serine protease that downregulates the hemostatic system through the 
proteolytic inactivation of factors Va and VIIIa. Protein C deficiency was first 
associated with thrombophilia in 1981.1 Heterozygous deficiency of protein 
C has a prevalence of 1 in 200 in the general population.2 The incidence 
of symptomatic disease in penetrant families is considerably higher than in 
the general population.3-6 The apparent variable penetrance of thrombotic 
disease among families with protein C deficiency has been attributed to the 
co-segregation of additional risk factors. Two likely candidates are the highly 
prevalent risk factors for thromboembolic disease, factor V Leiden and the 
prothrombin G20210A polymorphism.7,8
Since 1985, we have studied a large kindred of French-Canadian descent 
with an 8-fold increased risk of venous thrombosis and early onset of 
disease, associated with a 3363C insertion mutation in the protein C gene.3 
Segregation analysis suggested that the increased risk of thrombosis found 
in this kindred resulted from the interaction between the protein C 3363C 
insertion and another unknown genetic defect.9 Currently, we have identified 
787 family members, of whom 450 have been tested for the protein C 3363C 
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insertion. Factor V Leiden was found in only 4 individuals, and the G20210A 
prothrombin polymorphism was found in 13%. We found, however, no 
association between the G20210A prothrombin polymorphism and increased 
thromboembolic disease, despite the unusually high prevalence in this kindred, 
including a number of individuals with both protein C deficiency and the 
G20210A polymorphism.10 
Since increased thrombin generation has been associated with a higher 
prothrombin concentration in vivo11,12, we postulated a potential beneficial 
effect of increased thrombomodulin mediated activated protein C-generation 
in carriers of the prothrombin G20210A mutation. This hypothesis was 
not supported in a small preliminary study in which we correlated plasma 
concentrations of the protein C activation peptide, prothrombin fragment 
1+2 and fibrinopeptide A with prothrombin concentration. We observed a 
positive association of prothrombin concentrations with thrombin generation 
(fragment 1+2) and thrombin activity (fibrinopeptide A), but no association 
with protein C activation peptide levels.11 In the present study we have further 
evaluated this hypothesis in a larger sample of the family, by assessing the 
plasma concentration of the complex of activated protein C combined with 
protein C inhibitor (APC-PCI). Protein C inhibitor (PCI) is a molecular weight 
57 000 serine protease inhibitor with a plasma concentration of 90 nM.13,14 
Plasma concentrations of APC-PCI in part reflect the degree of activation of 
the protein C system. Previously described assays for APC-PCI have not been 
sensitive enough to accurately measure the full range of concentrations of 
the complex in healthy individuals. In this study we have utilized a new and 
highly sensitive assay for measuring the concentration of APC-PCI complex as 
a measure of the level of activation of protein C.15
Methods
Participants
Blood samples were collected from 201 family members of a large French-
Canadian kindred with type I protein C deficiency, including spouses of family 
members who have children. All samples were collected in 2002 into sodium 
citrate pH 4.3 Stabilyte tubes (Biopool, Umeå, Sweden). The ascertainment 
and evaluation of the family members was previously described.3 All subjects 
completed questionnaires regarding general demographic information, current 
health status, current medication, obstetric history, and personal history with 
regard to events (venous as well as arterial thrombosis and hemorrhages) 
and risk factors for venous thrombosis (i.e. surgeries, hospital admissions, 
bed rest, plaster cast). Completed forms were stored with only the patient 
identifier codes to protect patient confidentiality. All participating subjects gave 
informed consent. This study was approved by the Human Experimentation 
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Committee of the University of Vermont College of Medicine. 
Six individuals using oral anticoagulants at the time of the blood draw had 
levels of APC-PCI complex ranging from 0.01 to 0.03 μg/L. These individuals 
were excluded from all calculations. 
Laboratory methods
We measured protein C activity levels by performing a clot-based functional 
assay using a kit provided by Diagnostica Stago (Parsippany, NJ, USA).3,16 
The inter-assay coefficient of variation (CV) of this assay was 5.5%. The 
presence of the 3363C insertion in the protein C gene was determined by 
amplification of genomic DNA using a mutagenic oligonucleotide primer that 
in concert with the inserted C mutation creates a Bg1I cleavage site. The 
product was digested with Bg1I and analyzed on a 2% agarose gel.17 The 
prothrombin G20210A allele was detected by amplification of genomic DNA 
with a mutagenic primer resulting in a HindIII cleavage site when the A-allele 
was present.18
Concentrations of the APC-PCI complex were measured by a previously 
described assay.15 Samples were incubated with monoclonal biotinylated 
capture antibody M36 which recognizes a conformation dependent neo-
epitope in APC-PCI complexes.15,19 The mean level of APC-PCI complexes for a 
reference group, consisting of Swedish healthy individuals (n=80; mean age 
42 years; 20 men and 60 women), was 0.13 μg/L (range 0.07-0.26).20 The 
functional detection limit (intra-assay CV<20%) in Stabilyte plasma is 32 ng/L 
(unpublished data).
Statistical methods
SPSS was used to calculate the mean and 95% confidence intervals (CIs) 
(mean ±1.96 x standard error) of the levels of APC-PCI complex. Correlation 
analysis for levels of APC-PCI complex and protein C activity was performed by 
calculating Pearson’s correlation coefficient, and its non-parametric equivalent 
the Spearman’s rank correlation coefficient. Pearson correlation coefficients 
were similar to the Spearman’s rank correlation coefficients, but because 
the data were not normally distributed, only the latter are presented. For 
each Spearman’s rank correlation coefficient we calculated the 95% CI.21 
Correlations were calculated without accounting for the family structure. 
However, the heritability of APC-PCI and protein C were both low enough to 
perform analyses that do not account for family structure.22
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Results
APC-PCI levels and information on carriership of the prothrombin G20210A 
mutation were available for 55 family members with the protein C 3363C 
insertion and 140 family members without this mutation (35 were spouses). 
Of these 195 individuals, 83 were men (43%), 19 (10%) had experienced a 
venous thrombosis in the past, and the prothrombin mutation was present in 
24 of the family members (12%). The mean age at the blood draw was 41 
years (range 10-78 years).
Table 1 shows that family members with the protein C mutation had lower 
plasma concentrations of APC-PCI complex than individuals without the 
mutation. Protein C activity levels correlated highly with APC-PCI complex 
levels (n=195; rs=0.69; 95% CI 0.61-0.76). Figure 1 shows the scatterplot for 
the protein C activity levels and the APC-PCI complex levels with the exclusion 
of 2 subjects with APC-PCI complex concentrations of >1μg/L. The exclusion 
of these 2 individuals did not change the correlation coefficient (n=193; 
rs=0.68; 95% CI 0.59-0.75). The correlation was almost similar in family 
members with the protein C 3363C insertion (n=55; rs=0.50; 95% CI 0.26-
0.68) and family members without the protein C 3363C insertion (N=140; 
rs=0.44; 95% CI 0.29-0.57).
The levels of APC-PCI complex were not different between carriers and non-
carriers of the prothrombin G20210A mutation (Table 1), those with or without 
a history of venous thrombosis, or between men and women (data not 
shown). 
Table 1 APC-PCI complex levels (μg/L) of the family members 
                      APC-PCI complex 
n Mean (95% CI) Range 
Protein C 3363C insertion 55 0.08 (0.07-0.09) 0.01-0.17
+ PT G20210A 11 0.08 (0.07-0.10) 0.03-0.13
-  PT G20210A 44 0.08 (0.07-0.09) 0.01-0.17
No protein C 3363C insertion 140 0.18 (0.15-0.21) 0.07-2.20
+ PT G20210A 13 0.19 (0.14-0.23) 0.10-0.37
-  PT G20210A 127 0.18 (0.14-0.24) 0.07-2.20
Abbreviations: APC-PCI=activated protein C-protein C inhibitor, CI=confidence interval, PT=prothrombin
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Discussion
The prothrombin G20210A variant is clearly associated with an increased risk 
for venous thromboembolic disease18,23-25, as are the higher plasma levels 
of prothrombin associated with the A-allele.8,18,26,27 Thrombin generation, as 
reflected by prothrombin fragment 1+2 plasma concentration, varies directly 
with prothrombin concentration.11,12 This latter observation fits well with the 
increased risk of thrombosis associated with the mutation and raises questions 
with respect to the finding that the mutation does not confer risk in the 
presence of protein C deficiency in this French Canadian family.11 However, 
the findings of the present study do not support our hypothesis of increased 
protein C activation resulting from higher prothrombin concentrations 
associated with the prothrombin G20210A polymorphism. It is possible that 
the plasma concentration of APC-PCI does not reflect APC production, but the 
positive correlation between plasma protein C levels and APC-PCI does not 
support this explanation. The only described situation in which APC-PCI does 
not reflect APC production is when PCI has been depleted, such as in seriously 
Figure 1 Scatterplot of APC-PCI complex levels and protein C activity levels for 193 
family members with or without the protein C 3363C mutation (excluding 2 individuals 
with APC-PCI complex levels above 1 μg/L)
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ill septic or DIC patients.28 Thus, our findings suggest that if the observed 
higher levels of thrombin generation and activity compensate for the impaired 
protein C pathway in this thrombophilic family it must be by an alternative 
mechanism. 
Thrombin plays multiple roles in coagulation, fibrinolysis, platelet activation, 
cell growth, peripheral blood cell activation, anticoagulation, vascular 
endothelium and cell migration. Thus, the interaction of the prothrombin 
G20210A polymorphism with protein C deficiency in this thrombophilic 
kindred may not directly involve the protein C system. A recently described 
thrombin-mediated endothelial cell dependent mechanism for factor Va 
inactivation is a possible alternative mechanism.29 However, as is the case 
with this multifunctional protein, thrombin has also been shown to inhibit the 
inactivation of Factor Va by activated protein C in purified systems.30 Thus, we 
are left with an apparently paradoxical interaction of two well-established risk 
factors and an opportunity to learn more about the tonic thrombohemorrhagic 
balance first postulated by Åstrup in 1958.31
Reference List
1  Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of   
 protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-3.
2  Miletich J, Sherman L, Broze G, Jr. Absence of thrombosis in subjects with  
 heterozygous protein C deficiency. N Engl J Med 1987;317:991-6.
3  Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of  
 heterozygous protein C deficiency in a large New England kindred. Blood 
 1989;73:712-7.
4  Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased  
 risk of venous thrombosis in carriers of hereditary protein C deficiency defect.  
 Lancet 1993;341:134-8.
5  Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C   
 deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982;  
 48:1-5.
6  Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B,
 Gavasso S, Huisman MV, Büller HR, ten Cate JW, Girolami A, Prins MH.
 Incidence of venous thromboembolism in families with inherited   
 thrombophilia. Thromb Haemost 1999;81:198-202.
7  Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C   
 resistance as an additional risk factor for thrombosis in protein C-deficient  
 families. Blood 1994;84:1031-5.
8  Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, 
 Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of   
 the prothrombin gene increases the risk of thrombosis in subjects with familial  
 thrombophilia. Thromb Haemost 1997;78:1426-9.
9  Hasstedt SJ, Bovill EG, Callas PW, Long GL. An unknown genetic defect 
 increases venous thrombosis risk, through interaction with protein C   
84
I.5 No effect of the prothrombin G20210A mutation on protein C activation
85
I.5
 deficiency. Am J Hum Genet 1998;63:569-76.
10  Bovill EG, Hasstedt SJ, Callas PW, Valliere JE, Scott BT, Bauer KA, Long GL. 
 The G20210A prothrombin polymorphism is not associated with increased  
 thromboembolic risk in a large protein C deficient kindred. Thromb Haemost  
 2000;83:366-70.
11  Bovill EG, Bauer KA, Callas PW, Valliere JE, Scott BT, and Long GL.   
 Prothrombin concentration has a positive correlation with thrombin generation  
 but, a seemingly paradoxical, negative correlation with protein C activation in 
 a large protein C deficient kindred. Thromb Haemost 1999;82:216a.   
12  Bauer KA, Humphries S, Smillie B, Li L, Cooper JA, Barzegar S, Rosenberg  
 RD, Miller GJ. Prothrombin activation is increased among asymptomatic   
 carriers of the prothrombin G20210A and factor V Arg506Gln mutations.  
 Thromb Haemost 2000;84:396-400.
13 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human  
 plasma and characterization. J Biol Chem 1983;258:163-8.
14  Suzuki K. Activated protein C inhibitor. Semin Thromb Hemost 1984;10:154- 
 61.
15  Strandberg K, Kjellberg M, Knebel R, Lilja H, Stenflo J. A sensitive 
 immunochemical assay for measuring the concentration of the activated  
 protein C-protein C inhibitor complex in plasma: use of a catcher antibody  
 specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 
 2001;86:604-10.
16  Sala N, Owen WG, Collen D. A functional assay of protein C in human plasma.  
 Blood 1984;63:671-5.
17  Tomczak JA, Ando RA, Sobel HG, Bovill EG, Long GL. Genetic analysis of a  
 large kindred exhibiting type I protein C deficiency and associated thrombosis.  
 Thromb Res 1994;74:243-54.
18  Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation  
 in the 3’-untranslated region of the prothrombin gene is associated with   
 elevated plasma prothrombin levels and an increase in venous thrombosis.  
 Blood 1996;88:3698-703.
19  Strandberg K, Astermark J, Björgell O, Becker C, Nilsson PE, Stenflo J.   
 Complexes between activated protein C and protein C inhibitor measured  
 with a new method: comparison of performance with other markers of   
 hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost  
 2001;86:1400-8.
20  Strandberg K, Svensson A, and Stenflo J. Stabilyte tubes that contain strongly  
 acidic citrate prevent in vitro complex formation between activated protein C  
 and protein C inhibitor.  Thromb Haemost 2003;89:947-9. 
21  Zar JH. Biostatistical Analysis. 4th edition. Upper Saddle River, NJ: Prentice  
 Hall, 1999.
22 Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ,   
 Hoogendoorn H, Long GL, Scott BT, Bovill EG. Heritability of plasma   
 concentrations of clotting factors and measures of a prethrombotic state in a  
 protein C-deficient family. J Thromb Haemost 2004;2:242-7.
84
I.5 No effect of the prothrombin G20210A mutation on protein C activation
85
I.5
23  Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the   
 prothrombin gene is a common risk factor among Swedish outpatients with  
 verified deep venous thrombosis. Thromb Haemost 1997;78:990-2.
24  Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Férec C, Mottier D.  
 Prevalence of 20210 A allele of the prothrombin gene in venous 
 thromboembolism patients. Thromb Haemost 1998;80:49-51.
25  Margaglione M, Brancaccio V, Giuliani N, D’Andrea G, Cappucci G, Iannaccone  
 L, Vecchione G, Grandone E, Di Minno G. Increased risk for venous thrombosis  
 in carriers of the prothrombin G-->A20210 gene variant. Ann Intern Med  
 1998;129:89-93.
26  Simioni P, Tormene D, Manfrin D, Gavasso S, Luni S, Stocco D, Girolami A.  
 Prothrombin antigen levels in symptomatic and asymptomatic carriers of the  
 20210A prothrombin variant. Br J Haematol 1998;103:1045-50.
27  Kyrle PA, Mannhalter C, Béguin S, Stümpflen A, Hirschl M, Weltermann A,  
 Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical  
 studies and thrombin generation in patients homozygous or heterozygous for  
 the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 
 1998;18:1287-91.
28  Gruber A, Griffin JH. Direct detection of activated protein C in blood from  
 human subjects. Blood 1992;79:2340-8.
29  Hockin MF, Kalafatis M, Cawthern KM, Simioni P, Mann KG. A thrombin   
 mediated endothelial cell dependent mechanism for factor Va inactivation.  
 Blood 1998;92:183a.  
30  Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C  
 anticoagulant activity by prothrombin. Blood 1999;94:3839-46.
31  Åstrup T. The haemostatic balance. Thromb Diath Hemorrh (Stutt) 1958;2:  
 347-57.

Chapter II
Gene mapping in a protein C deficient family

Chapter II.1 
Heritability of plasma concentrations of clotting factors 
and measures of a prethrombotic state in a protein C 
deficient family
C.Y. Vossen, S.J. Hasstedt, F.R. Rosendaal, P.W. Callas, K.A. Bauer, G.J. Broze,
H. Hoogendoorn, G.L. Long, B.T. Scott, E.G. Bovill
Adapted from: 
Journal of Thrombosis and Haemostasis 2004; Vol. 2, 242-247
91
II.1
91
II.1
Summary
Earlier studies found strong support for a genetic basis for regulation of 
coagulation factor levels and measures of a prethrombotic state (D-dimer, 
prothrombin fragment 1.2). We wanted to estimate how much of the variation 
in the levels of coagulation factors and measures of a prethrombotic state, 
including measures of protein C activation and inactivation, could be attributed 
to heritability and household effect. Blood samples were collected from 330 
members of a large kindred of French-Canadian origin with type I protein 
C deficiency. Heritability and common household effect were estimated 
for plasma concentrations of prothrombin, factor V, factor VIII, factor IX, 
fibrinogen, von Willebrand factor (vWF), antithrombin, protein C, protein S, 
protein Z, protein Z-dependent protease inhibitor (ZPI), fibrinopeptide A (FPA), 
protein C activation peptide (PCP), activated protein C-protein C inhibitor 
complex (APC-PCI), activated protein C-α1-antitrypsin complex (APC-α1AT), 
prothrombin fragment 1.2 (F1.2) and D-dimer, using the variance component 
method in SOLAR. The highest heritability was found for measures of thrombin 
activity (PCP and FPA). High estimates were also found for prothrombin, 
factor V, factor IX, protein C, protein Z, ZPI, APC-PCI and APC-α1AT. An 
important influence of shared household effect on phenotypic variation was 
found for vWF, antithrombin, protein S and F1.2. In conclusion, we found 
strong evidence for the heritability of single coagulation factors and measures 
of a prethrombotic state. Hemostatic markers with statistically significant 
heritability constitute potential targets for the identification of novel genes 
involved in the control of quantitative trait loci. 
Introduction 
Over a century ago, Virchow postulated that thrombosis was caused by 
alteration in the vessel wall, blood flow or the composition of the blood.1 
Several hereditary prothrombotic defects have been identified in the last 
four decades associated with a change in the composition of the blood. The 
first hereditary defects described were mutations in clot-preventing factors 
(antithrombin, protein C and protein S).2-4 In 1994 and 1996, two highly 
prevalent mutations, the factor V Leiden mutation (FV G1691A) and the 
factor II G20210A mutation, were reported.5,6 The latter two mutations are 
associated with resistance to inactivation of activated factor V and elevated 
concentrations of prothrombin, respectively. Elevated concentrations of other 
procoagulant factors, such as fibrinogen, factor VIII, factor IX and factor 
XI have been shown to increase the risk of venous thrombosis.7-10 Several 
polymorphisms are known to influence plasma levels of fibrinogen.11 For high 
levels of factor VIII, evidence for a genetic determination by factors other 
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than blood group and von Willebrand factor has been found.12,13 However, 
no polymorphisms have been discovered yet in the factor VIII gene that can 
account for high levels of factor VIII.14 For factor IX and factor XI it is still 
unclear whether genetic factors contribute or not, and to what extent. 
Recent studies have demonstrated a genetic basis for the regulation of plasma 
concentrations of coagulation factors and markers of a prethrombotic state 
(D-dimer and F1.2) by estimating heritability within healthy individuals or 
relatives of individuals with arterial or venous thrombosis.15-18 Previously, we 
published preliminary data demonstrating strong evidence for the heritability 
of levels of markers of protein C activation and inactivation in a large family 
from French Canadian descent with type I protein C deficiency.19 
The present paper describes the finalized analysis on the heritability of levels 
of coagulation factors and measures of a prethrombotic state with the addition 
of important information on household influence. Heritability and common 
household effect were estimated for plasma concentrations of prothrombin, 
factor V, factor VIII, factor IX, fibrinogen, von Willebrand factor (vWF), 
antithrombin, protein C, protein S, protein Z, protein Z-dependent protease 
inhibitor (ZPI), fibrinopeptide A (FPA), protein C activation peptide (PCP), 
activated protein C-protein C inhibitor complex (APC-PCI), activated protein 
C-α1-antitrypsin complex (APC-α1AT), prothrombin fragment 1.2 (F1.2) and 
D-dimer.
Materials and methods
Participants and inclusion criteria
Blood samples were collected from 330 members of a large kindred of French-
Canadian origin with type I protein C deficiency, including spouses of family 
members with children. The ascertainment and evaluation of the family 
members was previously described.20 All subjects completed questionnaires 
and were personally interviewed regarding their medical history in general, 
their risk factors for thrombosis (e.g., use of birth control pills, pregnancy, 
surgery, trauma, infection) and their thrombosis history. We classified a history 
of venous thrombosis as verified when subjects were hospitalized and treated 
for venous thrombosis with an objectively diagnosed deep venous thrombosis 
or pulmonary embolism. All participating subjects gave informed consent, or if 
individuals were under 18, a parent or legal guardian gave informed consent. 
We excluded from all analyses women pregnant at the time of the blood 
draw (n=5). We also excluded individuals using coumadin derivatives (n=15) 
for vitamin K dependent factors (including all measures of a prethrombotic 
state), as well as individuals with fibrinogen levels below 100 mg/dl (n=3) and 
factor V levels below 33 U/dl (n=1). This study was approved by the Human 
Experimentation Committees of the University of Vermont College of Medicine, 
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Burlington (VT, USA) and the Beth Israel Hospital, Boston (MA, USA). 
Blood collection and processing
Peripheral blood was collected into siliconized glass Vacutainer tubes 
containing two different anticoagulants: 3.8% buffered citrate solution (Becton 
Dickinson, Franklin, NJ), and SCAT-1 (25 μM PPACK, 200 kIU/mL Aprotinin, 4.5 
mM EDTA, Haematologic Technologies, Essex, VT). Platelet poor plasma from 
freshly drawn whole blood was produced within one hour by centrifugation at 
3,000 x g for 10 minutes at room temperature and stored at –70ºC. Frozen 
plasma samples were thawed at 37ºC just before assay performance.
Assay methodology
All assays were performed in the investigators’ laboratories either by a clot-
based functional assay for protein C (coefficient of variation (CV) 5.5%)20,21, 
by ELISA: factor V antigen (CV 5.8%)22, factor VIII antigen (CV 7.8%), factor 
IX antigen (CV 10%), vWF (CV 3%)23, protein Z (CV 6.5%)24, ZPI (CV 7.2%)24, 
APC-α1AT complex (CV 12.4%)25 and APC-PCI complex (CV 11.7%)25, or radio-
immuno-assay: prothrombin (CV 8%)26, antithrombin (CV 5%)27,28, protein S 
(CV 9.8%)29, F1.2 (CV 8%)28, PCP (CV 14%)28 and FPA(CV 8%)28, the Clauss-
method for fibrinogen (CV 1.7%)30,31 using the ST4 instrument (Diagnostica 
Stago, Parsipanny, NJ, USA), or micro latex bead agglutination for D-dimer (CV 
9.2%) (Biomerieux, Durham, NC, USA)32,33. 
Factor V antigen analysis was performed with an in house assay.22 The kits for 
factor VIII antigen, factor IX antigen, protein C and vWF were provided by 
Diagnostica Stago (Parsippany, NJ, USA), and assays were performed following 
manufacturer’s instructions. The assays for activated protein C-PCI complex 
and APC-α1AT complex were performed using commercially available assay at 
Affinity Biologicals Inc. (Hamilton, Ontario, Canada).
The number of individuals per assay varied, based on the availability of 
appropriate stored samples from 83 to 287.
Statistical analysis     
To reduce skewness and kurtosis, we applied log transformation to the levels 
of factor V, vWF, antithrombin, FPA, PCP, APC-α1AT complex, APC-PCI complex 
and D-dimer, square root transformation to the levels of factor VIII antigen 
and F1.2, and reciprocal transformation to the levels of factor IX antigen.
Heritability, the proportion of the phenotypic variance attributed to polygenes, 
and common household effect, the proportion of the variance attributed to 
environmental factors shared within a household, were estimated for each 
variable using the variance component method in SOLAR.34 In addition we 
studied the effect on the heritability and household estimates of excluding 
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individuals with a definite venous thrombotic history, the protein C 3363C 
insertion and the prothrombin G20210A mutation. As only 3 family members 
carried the factor V Leiden mutation, we did not study the effect of excluding 
individuals with this mutation. The distribution of each (transformed) variable 
was assumed to be multivariate normal with a variance-covariance matrix 
following the formula: covariance (one person to another person)=h2K + 
c2H + e2I, with K derived from the kinship matrix, H from the household 
matrix and I from the identity matrix. The additive genetic and household 
components of variance were estimated using maximum likelihood analysis. 
The adjustment for covariates was made as part of the heritability analysis. 
All analyses were adjusted for age and sex. We also adjusted for the use of 
oral contraceptives or hormone replacement therapy for prothrombin, factor 
V, factor VIII antigen, fibrinogen, vWF, protein S and C, antithrombin, and all 
measures of a prethrombotic state. In addition, levels of vWF were adjusted 
for ABO blood group and levels of factor VIII antigen were adjusted for ABO 
blood group and in some analyses for vWF.
Results
The mean age of the 322 family members at the blood draw was 31 years 
(range 1-90), 131 (41%) were men and the mean body mass index (kg/m2) 
was 24.7 (range 12-52). The main characteristics of the 322 family members 
are outlined in Table 1. In total, 25% carried the 3363C insertion in the protein 
C gene, 13% carried the prothrombin G20210A polymorphism and 1% carried 
the factor V Leiden mutation, as confirmed by individual genotyping, and 
9% had experienced a definite venous thrombotic event. The mean level of 
prothrombin was 128.4 U/dl in individuals with the G20210A mutation (range 
90.7 to 165.0 U/dl).
Table 2 shows the mean level, standard deviation and range of all coagulation 
factors and measures of a prethrombotic state. The mean level and 95% CI 
ranges of levels of coagulation factors and measures of a prethrombotic state 
were largely in accordance with normal ranges found in our laboratory or by 
others20,35,36 We found slightly high levels for D-dimer in 7 family members. For 
factor VIII antigen levels we found a broad range, but most individuals with 
lower levels of factor VIII had correspondingly low levels of vWF and tended 
to have blood type O. 
  
Heritability and household estimates of single coagulation factors or markers
Table 3 shows heritability and household effect estimates for all coagulation 
factors and measures of a prethrombotic state. Among procoagulant factors, 
we found high heritability estimates for prothrombin (69.6%), factor V 
(71.4%) and factor IX antigen (50.3%) and lower heritability for fibrinogen 
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Table 1 Main characteristics of all subjects 
Characteristics at blood draw* (n=322)
Age (years;range) 31.3 (1-90)
Number of households 181 
Mean number of individuals per household (range) 1.8 (1-6)
Spouses 21
Sex (M/F) 131/191
Body mass index (kg/m2;range) 24.7 (12-52)
Smokers (age >13) 72/246 (29%)
Personal history of venous thrombosis (possible and definite events) 48/322 (15%)
Personal history of venous thrombosis (definite events) 28/322 (9%)
Anticoagulation treatment 15/322 (5%)
Hormone replacement therapy 10/181 (6%)
Oral contraceptive use 18/183 (10%)
Blood group O 80/290 (28%)
Protein C 3363C insertion 79/317 (25%)
Prothrombin G20210A mutation 38/293 (13%)#
Factor V Leiden mutation 3/302 (1%)
*Except for age, sex and body mass index, all characteristics are given as the number and percentage of 
individuals with the characteristic, including the number of individuals for whom information was available.
# One individual was homozygous for the prothrombin G20210A mutation.
(29.7%), vWF (25.3%), and factor VIII antigen when adjusted for vWF 
(19.5%). Interestingly, a household effect was found for vWF (30.7%), but 
not for factor VIII antigen (unadjusted for vWF) despite the relationship 
between factor VIII and its carrier protein vWF. Significant heritability 
estimates for anticoagulant factors were found for protein C (40.6% for all 
tested individuals; 38.5% excluding those with the 3363C insertion, and 5.2% 
in those with the 3363C insertion), protein Z (66.7%) and ZPI (42.8%). The 
estimates of heritability were low for antithrombin (6.1%), and protein S levels 
(10.5%), while for both substantial household effects were found (respectively 
33.5% and 36.9%). For measures of the activation and inactivation of protein 
C high heritability estimates were found for PCP (75.4%) and the APC-inhibitor 
complexes (58.6% for APC-α1AT and 58.4% for APC-PCI). FPA showed a 
high heritability (92.0%) likely reflecting the activity of thrombin. Heritability 
estimates, however, were low for prothrombin activation (F1.2; 22.1%) and 
D-dimer levels (6.6%), although for F1.2 a high household effect was found 
(44.1%). 
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No major differences (>30%) in heritability estimates or household estimates 
were seen after excluding family members with a definite history of venous 
thrombosis. However, we did find an increase or decrease of more than 30% 
in the heritability or household effects of several analytes after excluding 
individuals with the 3363C protein C gene insertion or the prothrombin 
G20210A mutation. Excluding individuals with the 3363C protein C mutation 
increased heritability and decreased the household effect for antithrombin 
to respectively 41% and 2.5%, and increased the household effect of 
prothrombin to 36%. Excluding individuals with the prothrombin G20210A 
mutation decreased heritability for prothrombin to 28% and increased 
heritability for APC-α1AT to 89%. 
Table 2 Mean levels, standard deviation and range of all analytes 
Analytes (units) n Mean SD Range 
Prothrombin (U/dl) 164 104.91 20.38 71.00-165.00
Factor V (U/dl) 259 117.75 37.13 54.76-299.75
Factor VIII antigen (U/dl)* 198 116.98 42.06 44.88-250.00
Factor IX antigen (U/dl) 222 93.08 30.69 52.87-250.00
Fibrinogen (mg/dl) 283 273.08 67.78 140.00-573.00
vWF (U/dl) 236 115.99 45.92 31.45-300.00
Antithrombin (% of normal) 176 98.23 16.52 64.10-161.60
Protein C (% of normal) 267 90.16 31.30 16.00-203.00
Protein C (3363C insertion only; % of normal) 59 50.68 15.11 16.00-109.00
Protein S (total; µg/ml) 163 15.35 2.48 8.00-24.10
Protein Z (% of normal) 274 104.50 36.02 21.00-237.00
ZPI (% of normal) 287 100.33 29.96 30.00-215.00
FPA (nM) 147 1.43 1.03 0.26-6.65
PCP (pmol/L) 83 1.33 0.74 0.25-4.17
APC-α1AT complex (nM) 164 0.28 0.49 0.01-4.30
APC-PCI complex (nM) 164 0.06 0.06 0.01-0.43
F1.2 (nmol/L) 147 2.28 1.56 0.40-10.20
D-dimer (ng/ml) 263 154.40 281.18 4.82-2551.48
Abbreviations: vWF=von Willebrand factor, ZPI=protein Z-dependent protease inhibitor, FPA=fibrinopeptide 
A, PCP=protein C activation peptide, APC-α1AT=activated protein C-α1-antitrypsin, APC-PCI=activated 
protein C-protein C inhibitor, F1.2=prothrombin fragment 1.2.  *Only individuals for whom blood type was 
known.
96
II.1 Heritability of clotting factors and markers
97
II.1
Table 3 Proportion of phenotypic variance explained by covariates, heritability (h2) 
and household effect (c2) 
Analytes N Proportion of variance %
covariates h2 SE (h2) c2 SE (c2)
Prothrombin 164 11.7 69.6* 18.1 4.1 15.0
Factor V 259 14.8 71.4* 13.3 2.8 9.5
Factor VIII antigen (adjusted for vWF) 187 46.1 19.5* 15.9 6.6 10.9
Factor VIII antigen 198 26.9 30.9* 15.2 0.0 N/a# 
Factor IX antigen 222 11.3 50.3* 19.0 3.3 12.0
Fibrinogen 283 24.3 29.7* 13.6 0.0 N/a# 
vWF 236 19.9 25.3* 16.4 30.7* 11.1
Antithrombin 176 23.1 6.1 13.4 33.5* 13.9
Protein C 267 3.3 40.6* 15.8 4.4 10.3
Protein S (total) 163 23.7 10.5 31.1 36.9* 21.7
Protein Z 274 0.0 66.7* 12.6 6.6 8.8
ZPI 287 7.4 42.8* 15.8 1.3 9.6
FPA 147 0.0 92.0* 15.9 0.0 N/a# 
PCP   83 5.6 75.4* 29.6 0.0 N/a#
APC-α1AT complex 164 1.8 58.6* 22.3 4.8 14.2
APC-PCI complex 164 0.0 58.4* 18.0 0.0 N/a #
F1.2 147 29.6 22.1 20.3 44.1* 13.3
D-dimer 263 13.5 6.6 12.9 5.2 10.3
Abbreviations: SE=standard error, vWF=von Willebrand factor, ZPI=protein Z-dependent protease inhibitor, 
FPA=fibrinopeptide A, PCP=protein C activation peptide, APC-α1AT=activated protein C-α1-antitrypsin, APC-
PCI=activated protein C-protein C inhibitor, F1.2=prothrombin fragment 1.2. *Significant at p<0.05. #No 
standard errors can be approximated for estimates of 0% or 100% in likelihood analysis.
Discussion  
This study was performed to establish evidence for a genetic basis for plasma 
concentrations of hemostatic markers known to confer risk for thrombosis. 
The highest heritability estimates were found for the measures of thrombin 
activity (PCP and FPA). These constitute the best potential targets for the 
identification of novel genes involved in the control of quantitative trait 
loci. High heritability was also found for prothrombin, factor V, factor IX 
antigen, protein C, protein Z, ZPI, APC-PCI and APC-α1AT. Fibrinogen, 
vWF, antithrombin, thrombin generation (F1.2) and endogenous fibrinolysis 
(D-dimer) showed low heritability. Heritability was also low for protein S; 
however, protein S differs from the other vitamin-K dependent factors in that 
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it is not a protease and is for 60% bound to C4b-bp in plasma. The heritability 
estimate for factor VIII antigen was low after adjustment for vWF levels, 
probably due to the dependance of factor VIII levels on the stabilization of 
factor VIII in plasma mediated by factor VIII binding to vWF. For protein C we 
found a heritability of 40.6% for all tested individuals, a heritability of 38.5% 
after excluding those with the 3363C insertion, and a heritability of 5.2% in 
those with the protein C 3363C insertion. The latter suggests that due to the 
lower sample size and having 1 active allele instead of 2, by chance, other 
genes affecting protein C may not be present or may not affect individuals 
with lower levels of protein C. 
An important influence of the shared household effect on phenotypic variation 
was found for vWF, antithrombin, protein S levels and F1.2. A household 
specific acute or chronic activation of the coagulation pathway by tobacco 
use, diet, physical activity or other shared environmental characteristics could 
explain the high household effects not only for F1.2 and vWF, but also for 
the anticoagulation factors protein S and antithrombin, as household specific 
differences in activation of the clotting system may give rise to compensatory 
differences in these inhibitors. 
Several other studies have estimated heritability with regard to the coagulation 
system but focused primarily on procoagulant and anticoagulant factors.15-18 
We found high heritability for markers of thrombin activation (FPA and PCP) 
and the activated protein C-inhibitor complexes. In contrast F1.2, a marker of 
thrombin generation, did not demonstrate significant heritability but did show 
a significant household effect. Adjustment for F1.2 in the present study did 
not change the heritability of FPA, PCP and the activated protein C-inhibitor 
complexes. Thus, thrombin generation, a critical step in hemostasis, seems 
to be influenced largely by environmental factors. However, its activity as 
measured by FPA, PCP and complexes of activated protein C with its inhibitors 
appears to be tightly controlled through genetic mechanisms which may 
implicate proteins like thrombomodulin, the endothelial cell protein C receptor 
and fibrinogen. Table 4 gives a comparison of the heritability estimates of 
the most recently published studies and the present study.15-18 The variance 
component method used to estimate heritability and household effect 
assesses the relative role of genetic and environmental causes of variation of 
a quantitative trait in a particular setting and population. Because genes and 
environment are different in various populations, heritability estimates cannot 
be readily compared quantitatively across populations. The populations shown 
in Table 4 are different not only by geography but also by selection of the 
sample from the population: De Souto et al.15 estimated heritability in family 
members of probands from multiple families with hereditary thrombophilia 
in Catalonia, Spain, whereas the studies by Ariёns et al. and De Lange et al. 
16,17 comprised healthy twins from the United Kingdom. We studied a single 
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kindred, which decreases both the genetic variance, due to familial genetic 
similarity, and the random environmental variance, due to greater similarity 
of lifestyles among different households within a family. Although the total 
variance is generally smaller in a single kindred compared to more varied 
populations, the increased genetic homogeneity facilitates the likelihood of 
detecting the gene(s) underlying the observed heritability. A potential source 
of error across populations could be attributed to the methods used to 
measure analytes with regard to the variation in pre-analytical and analytical 
errors, which could decrease heritability.37 We did not account for non-additive 
sources of genetic variance like dominance and epistasis, which could also 
decrease heritability. 
Table 4 Heritability estimates (h2,%) found in the present study and other studies
Analyte h2, %
USA UK-116,17 UK-218 Spain15
Prothrombin 70 57 Nd 49
Factor V 71 Nd Nd 44
Factor VIII antigen 20* 61# Nd 40#
Factor IX antigen 50 Nd Nd 39
Fibrinogen 30 44 35 34
vWF 25 75 Nd 32
Antithrombin 6 Nd Nd 49
Protein C 41 Nd Nd 50
Protein S 11 Nd Nd 46
Protein Z 67 Nd Nd Nd
ZPI 43 Nd Nd Nd
FPA 96 Nd Nd Nd
PCP 75 Nd Nd Nd
APC-α1AT complex 59 Nd Nd Nd
APC-PCI complex 58 Nd Nd Nd
F1.2 22 45 Nd Nd
D-dimer 7 65 Nd 11
Abbreviations: vWF=von Willebrand factor, ZPI=protein Z-dependent protease inhibitor, FPA=fibrinopeptide 
A, PCP=protein C activation peptide, APC-α1AT=activated protein C-α1-antitrypsin, APC-PCI=activated 
protein C-protein C inhibitor, F1.2=prothrombin fragment 1.2, Nd= not determined. *Adjusted for ABO 
blood group and vWF. #Not adjusted for ABO blood group and vWF.
Reprinted with permission from Elsevier.
100
II.1 Heritability of clotting factors and markers
101
II.1
The heritability estimates in this paper are only slightly different from the 
estimates we published earlier,19 and differ mainly due to the estimation of 
household effects. A shared household effect apparently seems to explain a 
part of the heritability previously published for levels of vWF, antithrombin and 
protein S,19 showing the importance of estimating household effects as part of 
a variance component analysis. Differences between studies in Table 4 could 
thus also be attributable to the magnitude of the household effect.
Exclusion of individuals with the 3363C insertion or the prothrombin G20210A 
mutation influenced few heritability and household estimates of coagulation 
factors or activation markers. An increase in the household effect after 
removal of carriers of a certain gene or trait could be the result of a decrease 
in the total variance, so that the household component accounts for more 
of the total variance. We have no explanation for the increase in heritability 
estimates after removal of carriers of a gene or trait other than that the 
inheritance of other genes fitted the polygenic model better once the gene-
carriers were removed. However, these changes can be used in defining the 
most informative subsets in subsequent quantitative trait loci linkage analysis. 
In conclusion, we found strong evidence for the heritability of single 
coagulation factors and measures of a prethrombotic state. Hemostatic 
markers with statistically significant heritability constitute potential targets for 
the identification of novel genes involved in the control of quantitative trait 
loci.38,39
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Summary
Previously we found a genetic basis for the variation in the plasma 
concentrations of several coagulation factors in a large pedigree with protein 
C deficiency. In addition, we estimated high heritabilities for markers of a 
prethrombotic state, including the plasma concentration of complexes of 
activated protein C (APC) with its main inhibitors α1-antitrypsin (α1AT) and 
protein C inhibitor (PCI). Performing variance component linkage analysis on 
the same pedigree, we found suggestive evidence for linkage (defined as a 
lod score between 1.9 and 3.3) on chromosome 19 at 34 cM (lod score 3.29) 
for plasma concentrations of APC-α1AT complex, and on chromosome 11 at 
146 cM (lod score 2.55) for plasma concentrations of APC-PCI complex. The 
identified linkage peaks did not seem the result of variation in the plasma 
concentrations of single coagulation factors related to the complex, i.e. PCI, 
α1AT and protein C. The areas with the lod scores suggestive of linkage were 
identified by relatively few markers and did not reveal obvious candidate 
genes. Fine-mapping in these regions with additional markers will both 
validate and narrow the regions of interest on chromosomes 11 and 19.
Introduction
Protein C is a vitamin K dependent zymogen, which after activation by the 
thrombin-thrombomodulin complex on the surface of endothelial cells down-
regulates the hemostatic system through the proteolytic inactivation of 
factors Va and VIIIa.1,2 Activated protein C is inhibited primarily by the serine 
proteinase inhibitors α1-antitrypsin and protein C inhibitor.3 Hereditary defects 
in the protein C gene have been associated with an increased risk of venous 
thrombosis4-6: a complex disease with an annual incidence of about 1 per 
1000 persons, which manifests itself mainly in the deep veins of the leg or 
the lungs, and which can be caused by several genetic and environmental 
risk factors.7,8 In 1989 we published the first data on a French Canadian 
kindred with an increased risk of venous thrombosis due to an insertion 
mutation in the protein C gene (3363_3364insC).9 Recently, we showed high 
heritability in this French Canadian kindred for plasma concentrations of the 
procoagulant factors, factor V, factor IX, and prothrombin, and the coagulation 
inhibitors protein C, protein Z and protein Z-dependent protease inhibitor.10,11 
In addition, we found evidence for a genetic basis for measures of thrombin 
activity (fibrinopeptide A and protein C activation peptide) and plasma 
concentrations of protein C inhibitor complexes (activated protein C-protein C 
inhibitor complex (APC-PCI) and activated protein C-α1-antitrypsin (APC-α1AT) 
complex).10,11 Our previous report demonstrated that over half of the variance 
in the APC-α1AT complex and APC-PCI complex plasma concentrations 
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could be attributed to genetic influences.10,11 As this thrombophilic kindred 
has an altered protein C system, we focused on assessing the regulation of 
this system through evaluating the genetic components responsible for the 
greater than half of the variance in these two major inhibitors in complex with 
activated protein C. The GAIT study, a family based study focussing on the 
Genetic Analysis of Idiopathic Thrombosis, localized earlier several quantitative 
trait loci (QTLs) of traits relevant to thrombosis like prothrombin, factor VIII 
and activated protein C resistance.12,13 Recently, they found evidence for a 
locus influencing normal variation in protein C levels on chromosome 16.14 The 
present report describes the results of a variance component linkage analyses 
performed on plasma concentrations of APC-α1AT and APC-PCI complexes.
Methods
Participants and inclusion criteria
Plasma concentrations of APC-α1AT and APC-PCI complexes were measured 
in members of a large kindred of French-Canadian origin with type I protein 
C deficiency, including spouses of family members with children. The 
ascertainment and evaluation of all family members was previously described.9 
All subjects completed questionnaires and were personally interviewed 
regarding their general medical history, risk factors for thrombosis (e.g., use of 
birth control pills, pregnancy, surgery, trauma, infection) and their thrombosis 
history. All participating subjects or their legal guardians gave informed 
consent. This study was approved by the Human Experimentation Committee 
of the University of Vermont College of Medicine, Burlington (VT). 
Blood collection, processing and assay methodology
Peripheral blood was collected into either of two siliconized glass Vacutainer 
tubes containing two different anticoagulants: 3.8% buffered citrate solution 
(Becton Dickinson, Franklin, NJ), or SCAT-1 (25 μM PPACK, 200 kIU/mL 
Aprotinin, 4.5 mM EDTA, Haematologic Technologies, Essex, VT). Platelet 
poor plasma from freshly drawn whole blood was produced within one hour 
by centrifugation at 3,000 x g for 10 minutes at room temperature and stored 
at –70ºC. Frozen plasma samples were thawed at 37ºC just before assay 
performance.
Plasma concentrations of APC-α1AT complex and APC-PCI complex were 
measured using a commercially available assay at Affinity Biologicals Inc. 
(Hamilton, Ontario, Canada). The inter-assay coefficients of variation 
(CVs) were 12%. The presence of the 3363C insertion in the protein C 
gene was determined by amplification of genomic DNA using a mutagenic 
oligonucleotide primer that in concert with the inserted C mutation creates a 
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Bg1I cleavage site. The product was digested with Bg1I and analyzed on a 2% 
agarose gel.15 The G20210A allele was detected by amplification of genomic 
DNA with a mutagenic primer resulting in a HindIII cleavage site when the A-
allele was present.16 To test whether the identified linkage peaks might be the 
result of variation in the plasma concentrations of single coagulation factors 
related to the complex or to thrombin generation, we also performed variance 
component linkage analyses for plasma concentrations of protein C, α1AT, PCI 
and prothrombin fragment 1.2 (F1.2). We measured protein C activity levels 
with a clot-based functional protein C activity assay using the Staclot Protein 
C kit provided by Diagnostica Stago (Parsippany, NJ, USA). The inter-assay 
CV of this assay was 6%. Alpha1-antitrypsin plasma concentrations were 
measured performing rate nephelometry using a Beckman-Coulter Image with 
an inter-assay CV of 4%. Both the protein C activity and α1-antitrypsin assays 
were performed following manufacturer’s instructions. PCI (PAI-3) plasma 
concentrations were measured performing an ELISA using a kit from Enzyme 
Research Laboratories (South Bend, IN, USA) with an inter-assay CV of 4%. 
Prothrombin activation fragment 1.2 (F1.2) concentrations were measured by 
a radio-immuno-assay with an inter-assay CV of 8%.17 
Data analysis
Genotyping was performed with 375 autosomal markers by the NHLBI 
Mammalian Genotyping Service at the Marshfield Medical Research Foundation 
18 using Screening Set version 10. Marker spacing averaged 9.4 cM (range 
0-18 cM) with an average marker heterozygosity of 75% (range 42-89%). 
As described previously19, genotype data were checked for pedigree and 
genotyping errors using Eclipse220 and Simwalk221,22, and the marker allele 
frequencies were estimated in PAP.23 The probability of Identity By Descent 
(IBD) was estimated using the multipoint IBD method in Simwalk221 which 
uses the proportion of alleles shared identical by descent at marker loci to 
estimate IBD sharing at arbitrary points along the chromosome for each 
relative pair. Input files were produced using MEGA2.24
Subsequently, using SOLAR (Sequential Oligogenic Linkage Analysis 
Routines)25, we performed variance component linkage analysis to test 
whether a proportion of the genetic variance in the plasma concentrations of 
APC-α1AT complex or APC-PCI complex could be attributed to specific genomic 
locations. The plasma concentrations of APC-α1AT and APC-PCI complexes 
were log-transformed to reduce skewness (from 5.4 to 0.0 for APC-α1AT; 
from 3.0 to 0.2 for APC-PCI) and kurtosis (from 33.9 to 0.4 for APC-α1AT; 
from 11.6 to 0.4 for APC-PCI). Of the levels of protein C we took the square 
root to reduce skewness from 0.4 to –0.1 (kurtosis went from 0.3 to -0.2), 
levels of PCI, α1AT and F1.2 were log-transformed to reduce skewness from, 
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respectively, 0.6 to –0.1, 0.6 to 0.0 and from 2.1 to 0.2. Kurtosis decreased 
from 1.0 to –0.1 for PCI, from 0.8 to 0.3 for α1AT (after removing 2 outliers) 
and from 5.9 to -0.1 for F1.2. All (transformed) levels were assumed to 
distribute as a multivariate normal density with correlation=h2K + c2H + 
q2B + e2I, where matrix K contains the kinship coefficients, H contains 1 
for pairs from the same household and 0 otherwise, B contains the IBD 
probabilities, and I represents the identity matrix. The parameters for 
heritability (h2), household effect (c2), and heritability contributed to a specific 
genomic location (q2) as well as the effects of the covariates were estimated 
simultaneously using maximum likelihood analysis. Lod scores were computed 
as the log10 likelihood for q
2 estimated to q2=0. A lod score of 3.3 was used 
as cut-off point for statistical evidence for significant linkage as suggested 
by Lander and Kruglyak, and a lod score of 1.9 but below 3.3 for suggestive 
linkage evidence.26 By including covariates in the linkage model, which might 
absorb some of the variation, we tried to increase the proportion of variation 
due to a QTL. These covariates were characteristics that have a documented 
effect on the activation state of the hemostatic system: age, sex, use of 
oral contraceptives or hormone replacement therapy, and presence of the 
protein C mutation.17,27-29 Individuals on coumarin derivatives (n=15), women 
pregnant at the time of the blood draw (n=6) or women for whom we had no 
information on the use of female hormones (n=6) were not included in the 
analysis. Among the subjects on coumarin derivatives the mean APC-α1AT 
complex level was 0.09 nM (range 0.02-0.27; n=9), and the mean APC-PCI 
complex level was 0.02 nM (range 0.01-0.05; n=10).
Results 
Of all genotyped family members who fulfilled the above criteria, 135 subjects 
were tested for plasma concentrations of APC-α1AT complex and 129 for 
plasma concentrations of APC-PCI complex (125 subjects were tested for both 
complexes). The main characteristics of the participants are depicted in Table 
1. A preponderance of the participants was female. Table 2 shows the mean 
plasma concentrations of the plasma concentrations of APC-α1AT complex, 
APC-PCI complex, protein C activity levels, α1-antitrypsin, PCI and F1.2.
The variance component linkage analysis based on the Marshfield map for 
the 22 autosomes revealed lod scores above 1 for chromosomes 3, 10, 11, 
13, 18 and 19 for plasma concentrations of APC-α1AT (Table 3). The highest 
lod score was found for a region on chromosome 19 (34 cM Marshfield Map, 
nearest marker D19S586), showing evidence for linkage with a lod score of 
2.77. In addition, a lod score of 2.01 was found on chromosome 13 (54 cM 
Marshfield Map, nearest marker D13S800); however, this lod score dropped 
to 1.29 after accounting for the region on chromosome 19 by computing a 
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lod score relative to the chromosome 19 maximum. Including the covariates 
age, sex and female hormones in the model resulted in a lod score of 3.29 
at 34 cM at chromosome 19 with a heritability estimated at 77% (standard 
error 23%), no apparent household effect (0%), and with 2% of the total 
variance explained by the covariates. Adding protein C mutation status as a 
covariate did not drastically lower the lod score (lod score: 3.0). The removal 
of family members with verified venous thrombosis (n=8) decreased the lod-
score to 2.60 at chromosome 19 (at 35 cM; accounting for the effect of age, 
sex and use of female hormones). Figure 1 shows the peak on chromosome 
Table 1 Main characteristics of all participants at the time of the blood draw
Characteristics Subjects 
APC-α1AT complex 
measured
(n=135)
APC-PCI complex 
measured
(n=129)
Mean age at blood draw (years (range)) 28 (1-75) 29 (1-75)
Sex (Males/Females) 60/75 56/73
Number of households (n) 95 92
Individuals per household (mean (range)) 1.4 (1-4) 1.4 (1-4)
Spouses (n) 0 0
Protein C 3363C insertion carriers (n (%)) 28 (21) 25 (19)
Prothrombin G20210A mutation carriers (n (%)) 28 (21)* 28 (22)*
Factor V Leiden mutation carriers (n (%)) 0 (0) 0 (0)
Venous thrombosis history** (n (%)) 20 (15) 19 (15)
Definite venous thrombosis history (n (%)) 8 (6) 8 (6)
OCC users (age 10-40) (n/total n (%)) 11/55 (20) 11/54 (20)
HRT users (age>40) (n/total n (%)) 2/11 (18) 0/12 (0)
*One was homozygous for the prothrombin G20210A mutation. **Both possible and definite events.
Table 2 Mean plasma concentrations, standard deviations and ranges of all analytes 
Analyte (units) N Mean SD Range
APC-α1-antitrypsin complex (nM) 135 0.30 0.53 0.01-4.30
APC-protein C inhibitor complex (nM) 129 0.07 0.06 0.01-0.43
Protein C activity (% of normal) 229 92.9 30.8 25.0-203.00
α1-antitrypsin (mg/dl) 124 132.7 24.8 79.0-214.0
Protein C inhibitor (% of normal) 150 151.4 36.8 74-301
F1.2 (nmol/L) 119 2.4 1.7 0.4-10.2
Abbreviations: SD=standard deviation, F1.2=prothrombin fragment 1.2
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Table 3 Lod scores above 1 for APC-α1-antitrypsin complex.
Chromosome Closest marker Location Lod Score
3 D3S3630 11 1.07
10 D10S1248 168 1.13
11 ATA34E08 29 1.51
13 D13S800 54 2.01
18 D18S1371 114 1.15
19 D19S586 33 2.77
Figure 1 Lod scores on chromosome 19 for APC-α1-antitrypsin complex (solid), pro-
tein C (dashed; peak at 47 cM), α1-antitrypsin (dashed; no peak) and F1.2 (dashed; 
peak at 56 cM) adjusted for age, sex, and female hormones  
19 on all 135 subjects in detail. The 95% confidence interval around the peak, 
approximated by a one-unit lod score drop on both sides of the peak, ranged 
from 25 cM to 38 cM. 
The variance component linkage analysis performed for plasma concentrations 
of APC-PCI complex estimated lod scores above 1 on chromosomes 5,11,17 
and 18 (Table 4), all of which were below a lod score of 1.9, the cut-off point 
for suggestive linkage evidence. Including age as a covariate increased the 
lod score on chromosome 11 to 2.08 with a heritability estimated at 53% 
(standard error 20%), no apparent household effect (0%) and with 2.8% of 
the variance explained by age. The removal of family members with venous 
thrombosis (n=8) increased the lod-score to 2.55 (with age included in the 
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Figure 2 Lod scores on chromosome 11 for APC-PCI (solid), protein C (dashed; no 
peak), PCI (dashed; peak at 56 cM) and F1.2 (dashed; peak at 48 cM) adjusted for 
age in subjects without a history of venous thrombosis.
model) at chromosome 11 (146 cM). Figure 2 shows the peak for chromosome 
11 in the 121 subjects without venous thrombosis. The 95% confidence 
interval around the peak ranged for the region on chromosome 11 from 119 to 
147 cM. 
Table 4 Lod scores above 1 for APC-PCI complex
Chromosome Closest marker Location Lod Score
5 D5S2500 73 1.73
11 D11S969 145 1.78
17 D17S2196 39 1.27
18 D18S877 51 1.73
Plasma concentrations of protein C, α1AT and thrombin activation might 
affect the plasma concentrations of APC-α1AT and APC-PCI. Levels of protein 
C and prothrombin fragment 1.2 had been measured already in some of 
the genotyped family members. In addition, we recently measured α1AT 
and PCI plasma concentrations. No evidence for linkage was observed on 
chromosomes 11 and 19 for protein C and F1.2 plasma concentrations, and on 
chromosome 11 for PCI and chromosome 19 for α1AT plasma concentrations, 
using the same exclusion criteria and adding the same covariates for both 
complexes as in the above analysis (Figures 1 and 2). 
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Discussion
Variance linkage component analysis identified a quantitative trait locus 
on chromosome 19p13 influencing the plasma concentration of APC-
α1AT complex (lod score 3.29; 34 cM), and a quantitative trait locus on 
chromosome 11q25 influencing the plasma concentration of APC-PCI complex 
(lod score 2.55; 146 cM). Thus, although both of these serine protease 
inhibitors (serpins) are closely related and are coded in the same cluster 
on 14q32.1, we found different chromosomal regions influencing levels of 
APC in complex with one of these inhibitors. Although the two inhibitors are 
structurally related, they differ functionally as demonstrated by the finding 
that PCI activity can be regulated by heparin in contrast to α1AT activity.30 
In addition, α1AT contains a single reactive site centered at a Met358-Ser359 
sequence 36 amino-acid residues from the C-terminus, whereas for PCI the 
reactive site peptide bond is located at Arg354-Ser355. We previously reported 
evidence for linkage of thrombosis in region 11q23 (106 cM; p=0.043), which 
is relatively distant from the region found for APC-PCI complex (146 cM), and 
found no evidence for linkage with thrombosis on chromosome 19 (p-value 
on chromosome 19 in that area ranged from 0.80 to 0.95).19 Both complexes 
are likely to be intermediate phenotypes for venous thrombosis according to a 
study by España et al31, who found high levels of both complexes in patients 
with deep venous thrombosis. However, Watanabe et al32 only found increased 
levels of APC-PCI complex and not APC-α1AT complex in patients with deep 
venous thrombosis and pulmonary embolism. 
Genes regulating plasma concentrations of protein C or the activation of 
protein C could have influenced the plasma concentrations of APC-α1AT 
complex and APC-PCI complex. However, it seems unlikely that plasma 
concentrations of protein C influenced the plasma concentrations of APC-α1AT 
and APC-PCI complex for the following reasons: the gene for protein C lies 
on chromosome 2, accounting in the analyses for the effect of the protein C 
3363C mutation did not dramatically decrease the lod score and linkage was 
not observed for protein C plasma concentration on either chromosome 11 
or 19. The plasma concentrations of the inhibitors might determine some of 
the variance in the concentrations of the complexes. Local regulatory events 
involving control of transcription appear to be excluded by the absence of 
linkage on chromosome 14 where the genes for α1AT and PCI are located, 
and no linkage evidence was found for either PCI or α1AT on, respectively, 
chromosome 11 and chromosome 19. Plasma concentrations of free α1AT 
or PCI could also have been influenced through complex formation with 
target proteases other than APC, or by inactivation of free α1AT or PCI by 
metalloproteases. No obvious candidate genes were found in the regions on 
chromosomes 11 and 19 that would influence clearance or post-translational 
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processing of protein C, α1AT or PCI. 
As specific candidate genes were not identified in the regions of linkage, it 
appears that yet to be determined genes in these regions explain over half the 
variance in these protease inhibitor complexes. The next stage of this study 
will be to fine-map the locations identified on chromosomes 11 and 19 to 
validate the quantitative trait loci and narrow the regions containing potential 
candidate genes.
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Rationale and aims of this thesis
Venous thrombosis is a common disease, which manifests mostly in the deep 
veins of the leg, with a reported incidence of 1-2 per 1000 individuals per 
year.1,2 Several genetic risk factors have been identified for venous thrombosis: 
mutations in the natural coagulation inhibitors protein C, protein S and 
antithrombin, and in the procoagulant factors prothrombin and factor V.3-7 
It is, however, difficult to predict the risk of venous thrombosis for carriers 
of these defects, as venous thrombosis manifests itself as a multicausal 
disease, in which multiple genetic and environmental factors play a role and 
can interact in the onset of disease.8-10 In families with a clear tendency to 
develop venous thrombosis (thrombophilia) the presence of multiple genetic 
risk factors explains the higher risk in individuals from these families compared 
with individuals with the same defect without a family history of venous 
thrombosis.11,12 Large studies on the risk of venous thrombosis associated 
with familial thrombophilia are scarce, mainly because families with defects in 
natural anticoagulant inhibitors are rare. This has precluded the formulation 
of rational guidelines on thrombophilia testing and the duration of anti-
coagulation treatment in these families. We wanted to address this paucity 
of evidence by initiating a prospective cohort study including individuals with 
inherited thrombophilia from different European thrombosis centers with 
expertise on thrombophilia research: the EPCOT study. The first part of this 
thesis (Chapter I) mainly describes the results of this study regarding the risk 
of a first or recurrent venous disease or a first fetal loss in carriers of known 
familial defects. 
According to the literature, only in 13% of the thrombophilia families at least 
two genetic factors can be found, whereas in 60% of the families one genetic 
risk factor and in 27% of the families no risk factor can be found13, despite the 
belief that families with a high tendency to venous thrombosis carry multiple 
defects.11,12 Thus, the currently known genetic defects can explain only partly 
the increased risk of venous thrombosis in thrombophilic families. This was 
underlined by the evidence found in a large kindred with protein C deficiency 
for the presence of an unknown second major gene defect, which increased 
the risk of venous thrombosis in interaction with the protein C 3363C 
mutation.14 Chapter II focuses on finding new genetic risk factors for venous 
thrombosis in the protein C deficient kindred by searching for genes regulating 
intermediate hemostatic phenotypes like plasma concentrations of factor VIII. 
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Results and general discussion
Inherited thrombophilia and the risk of venous thrombosis and fetal loss: the 
EPCOT study
A total of 2838 participants were included in the EPCOT study: 1626 with 
familial thrombophilia, and 1212 friends or partners as controls (representing 
the general population). Chapter I.1 describes the lifetime risk of venous 
thrombosis in all subjects (thrombophilia and control subjects) before 
they entered the EPCOT study. In total, 600 probands, the first of a family 
identified with a prothrombotic defect, and 846 relatives with a genetic defect 
were included in the analysis. Of these thrombophilic subjects and the 1212 
controls, 532 probands (89%), 139 relatives (16%) and 15 controls (1%) had 
experienced a venous event in the deep veins of the legs or the lungs before 
study entry. Recurrent events already had occurred in 288 probands (54%), 
58 relatives (42%) and 2 controls (13%). The incidence of venous events 
experienced before study entry in relatives was 4.4 (95% CI 3.7-5.2) per 1000 
person years and in controls 0.3 (95% CI 0.2-0.5) per 1000 person years with 
a relative risk of 16.4 (95% CI 9.6-28.0), adjusted for sex and center effects 
(Table 1). Considerable differences in the lifetime risk of venous thrombosis 
were found among individuals with different thrombophilic defects. We found 
the highest incidence of events in the relatives with combined defects (8.4 per 
1000 person years), as has been described by other authors.11,15-18 For single 
defects we found the highest risk in subjects with protein S deficiency (7.1 per 
1000 person years), and the lowest risk was associated with factor V Leiden 
(1.5 per 1000 person years), although several others have shown that the 
greatest venous thrombotic risk is associated with antithrombin deficiency.19-22 
Obviously, we might have underestimated the risk of venous thrombosis as we 
only counted follow-up years for subjects who had entered in the cohort, and 
therefore individuals, who had died of a fatal venous event before the start of 
the study were not included. However, in previous studies we have shown that 
the mortality of antithrombin deficiency23, protein C deficiency24 and factor V 
leiden25 does not exceed the population risk. 
Chapter I.2 shows the prospective data on the risk of a first venous event 
in subjects with thrombophilia, which was analyzed in 575 thrombosis-free 
relatives and 1118 controls receiving no long-term (i.e. for more than one 
year) anticoagulation treatment during prospective follow-up. In total, 26 
thrombophilic subjects (4.5%) and 7 controls (0.6%) experienced a first 
venous thrombotic event in the deep veins or in the lungs during prospective 
follow-up. In 15 thrombophilic individuals (58%) and 3 controls (43%) these 
events occurred spontaneously, i.e., in the absence of established risk factors 
such as surgery, pregnancy or immobilization. The incidence of a first deep 
venous thrombosis or pulmonary embolism was 0.8% per year in relatives 
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compared with 0.1% per year in controls with a relative risk of 9.0 (95% 
CI 3.8-21.1), adjusted for sex, age and center effects (Table 1). Again, the 
incidences differed considerably for different thrombophilia defects: it was 
highest for antithrombin deficiency (1.7%/year) and combined defects (1.6%/
year), and again lowest for factor V Leiden (0.1%/year). Reports from other 
studies include higher, similar and also lower risks for the various defects, 
which might be due to differences in study design.17,19-22,26-32 Overall, we found 
a higher incidence of a first event in the prospective analysis than in the 
retrospective analysis (Table 1). Since the follow-up time for the retrospective 
study was from birth until inclusion in the study, the incidence rates will 
have been diluted as the risk of venous thrombosis until the age of 15 is 
very low. In contrast, the relative risk of a first venous event associated with 
thrombophilia was higher in the retrospective analysis than in the prospective 
analysis (Table 1). On the one hand, this could be due to mainly selecting 
symptomatic relatives at inclusion, which increases the incidence rates of the 
thrombophilia subjects in the retrospective analysis, and on the other hand 
the incidence rates in the prospective analysis could have been lower due 
to increased care for those subjects. Since no inception cohort was formed 
for the retrospective analysis, we consider the prospective design as more 
reliable. 
Chapter I.3 describes the recurrence rate of venous thrombosis during 
prospective follow-up in all patients, both probands and relatives, with a 
thrombophilic defect and only one deep venous thrombosis or pulmonary 
embolism before study entry. Forty-four of the 180 (24%) patients who did 
not receive long-term anticoagulation and 7 of the 124 (6%) patients who 
were on long-term anticoagulation experienced a recurrent deep venous 
thrombosis or pulmonary embolism. The recurrence rate in the absence of 
long-term anticoagulation was 5.0% per year (95% CI 3.6-6.7), and thus 
much higher than the incidence of a first event (Table 1). However, the overall 
recurrence rate was not much different from that found for consecutive 
patients with a first thrombotic event with reported incidences ranging from 
13-28% over 5 years of follow-up.33-36 As in Chapter I.2, the lowest rate was 
found in thrombophilia subjects with factor V Leiden, and the highest rate in 
subjects with antithrombin deficiency. When we restricted the analysis to men, 
who had a 3-fold higher risk of venous thrombosis than women, much higher 
recurrence rates (around 11% per year) were found in men with deficiencies 
of protein C, protein S, and those with multiple defects than in women (2-
3% per year). For men and women with antithrombin deficiency the risk was 
similar (respectively 12% and 10% per year). The recurrence rate was 80% 
lower for patients on long-term anticoagulation (1.1% per year; 95% CI 0.4-
2.2) and was almost similar to the incidence of first events in thrombophilic 
participants (Table 1), but the use of long-term anticoagulation treatment also 
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resulted in a risk of major hemorrhage of 0.8% per year. 
From the results on the risk of venous events (Chapters I.1-3) we could not 
infer a clear benefit for long-term anticoagulation treatment in preventing a 
first event, as the risk of a first venous thrombosis (Table 1) was in general 
not substantially higher than the risk of major hemorrhages associated 
with anticoagulant therapy (requiring hospitalization or surgery, or leading 
to death), which is reported to lie between 1 and 3%.37,38 In addition, the 
recurrence rate in thrombophilia patients was not higher than in consecutive 
patients, for whom long-term anticoagulation treatment is not recommended 
in clinical practice after a first event.39-42 However, our study is an 
observational study, and only randomized trials can demonstrate whether the 
benefit from long-term treatment is indeed not sufficient. The EPCOT study 
can only give rough guidelines based on the absolute risks found, especially as 
the treatment policies differ per center, but the results can assist physicians in 
decisions on testing on thrombophilic abnormalities and choices about long-
term anticoagulation after a first thrombosis. It is important to keep in mind 
that the results from the EPCOT study can only be generalized to individuals 
from thrombophilic families, but not to unselected individuals with the same 
defect, as we have previously shown that these individuals have a lower risk 
of thrombosis.11,12
A secondary aim of the EPCOT study was to study the risk of fetal loss in 
women with thrombophilia. Thirty-nine women with thrombophilia and 51 
control women in the EPCOT study had not experienced a fetal loss (i.e. any 
loss during pregnancy) before study entry and did not use any anticoagulants 
during the first pregnancy in the prospective follow-up. Of these women, 
the first pregnancy during prospective follow-up ended in fetal loss in 7 of 
the 39 women with thrombophilia and 7 of the 51 control women (relative 
risk 1.4; 95% CI 0.4-4.7) (Chapter I.4). Per type of defect the relative risk 
varied only minimally from 1.4 for factor V Leiden to 1.6 for antithrombin 
deficiency compared to control women. Similar results were found in the 
analysis of the baseline data.43 Hence, the likelihood of a positive outcome is 
high in both women with thrombophilia and in controls. During prospective 
follow-up, 83 women with thrombophilia used heparin or oral anticoagulants 
during pregnancy. However, we could not draw solid conclusions on the 
benefit of thromboprophylactic treatment on the pregnancy outcome due to 
the differences in dose, type and starting point of treatment. As the risk of a 
first fetal loss without thromboprophylaxis was only mildly increased in this 
analysis, a strong beneficial effect of thromboprophylactic treatment is not 
likely. 
122
Summary
123
Su
Ta
bl
e 
1 
O
ve
rv
ie
w
 E
PC
O
T 
da
ta
 o
n 
th
e 
ris
k 
of
 a
 fi
rs
t 
an
d 
se
co
nd
 v
en
ou
s 
th
ro
m
bo
tic
 e
ve
nt
Re
tr
os
pe
ct
iv
e 
da
ta
  
(C
ha
pt
er
 I
.1
)
Ri
sk
 o
f a
 fi
rs
t 
ev
en
t
Pr
os
pe
ct
iv
e 
da
ta
 
(C
ha
pt
er
 I
.2
)
Ri
sk
 o
f a
 fi
rs
t 
ev
en
t
Pr
os
pe
ct
iv
e 
da
ta
 
(C
ha
pt
er
 I
.3
)
Ri
sk
 o
f a
 s
ec
on
d 
ev
en
t
Th
ro
m
bo
ph
ili
a 
su
bj
ec
ts
Co
nt
ro
ls
Th
ro
m
bo
ph
ili
a 
su
bj
ec
ts
Co
nt
ro
ls
Th
ro
m
bo
ph
ili
a 
su
bj
ec
ts
 w
ith
 A
C
Th
ro
m
bo
ph
ili
a 
su
bj
ec
ts
 w
ith
ou
t 
AC
N
um
be
r 
of
 s
ub
je
ct
s
84
6
12
12
57
5
11
18
12
4
18
0
N
um
be
r 
of
 s
ub
je
ct
s 
w
ith
 e
ve
nt
 
13
9
15
26
7
7
44
Pe
rs
on
 y
ea
rs
 o
f a
ll 
su
bj
ec
ts
 
31
66
0
51
07
9
31
94
62
70
65
2
88
2
In
ci
de
nc
e 
in
 %
/y
ea
r 
(9
5%
 C
I)
 
0.
4 
(0
.4
-0
.5
)
0.
0 
(0
.0
-0
.1
)
0.
8 
(0
.5
-1
.2
)
0.
1 
(0
.0
-0
.2
)
1.
1 
(0
.4
-2
.2
)
5.
0 
(3
.6
-6
.7
)
Re
la
tiv
e 
ris
k
16
.4
 (
9.
6-
28
.0
)*
9.
0 
(3
.8
-2
1.
1)
**
0.
2 
(0
.1
-0
.4
)*
*
Ab
br
ev
ia
tio
n:
 A
C=
an
tic
oa
gu
la
nt
 t
he
ra
py
, C
I=
co
nfi
de
nc
e 
in
te
rv
al
 *
Ad
ju
st
ed
 fo
r 
se
x 
an
d 
ce
nt
er
 e
ffe
ct
s 
**
Ad
ju
st
ed
 fo
r 
se
x,
 a
ge
 a
t 
en
tr
y 
an
d 
ce
nt
er
 e
ffe
ct
s
122
Summary
123
Su
Gene-gene interaction and gene mapping in a large protein C 
deficient kindred 
Besides the EPCOT study, this thesis describes data from a large family with 
protein C deficiency. In this protein C deficient kindred, unexpectedly, a lack 
of interaction between the prothrombin G20210A mutation and the protein C 
3363C mutation was found, and therefore no increase in the risk of venous 
thrombosis in family members who carried both mutations. We postulated 
a potential beneficial effect on activated protein C (APC) generation in 
carriers of the prothrombin G20210A mutation due to increased thrombin 
generation associated with this variant. This hypothesis could, however, 
not be substantiated as we found no association between the prothrombin 
G20210A variant and protein C activation, as measured indirectly by 
measuring plasma concentrations of APC in complex with protein C inhibitor 
(PCI) with a new and highly sensitive assay (Chapter I.5). For this analysis, 
blood samples were used from 195 family members, of whom 55 carried the 
protein C 3363C mutation, and 24 carried the prothrombin G20210A mutation. 
Protein C activity levels correlated positively with APC-PCI complex plasma 
concentrations (r=0.69). However, APC-PCI complex levels were not different 
for carriers of the prothrombin G20210A mutation compared with non-carriers. 
Therefore, our findings suggest that if the observed higher levels of thrombin 
generation and activity compensate for the impaired protein C pathway in this 
thrombophilic family, it must be by an alternative mechanism. 
For the identification of genes or gene variants influencing the risk of complex 
diseases generally two main approaches are applied: linkage studies using 
data on related individuals (e.g., family studies) and association studies using 
data on unrelated individuals (e.g., case-control studies). Family studies are 
very useful for the identification of rare but relatively strong alleles, whereas 
case-control studies can be used to identify common (and generally also 
weaker) gene variants. In the protein C deficient kindred evidence was found 
for the presence of an unknown genetic defect, which strongly increased the 
risk of venous thrombosis in interaction with the protein C 3363C insertion in 
this kindred.44 We started a search for unknown genes influencing thrombosis 
risk using the linkage study approach, when genetic screening of 34 candidate 
genes involved in hemostasis or inflammation provided no evidence that any 
of these candidate genes, including factor V Leiden and the prothrombin 
G20210A variant, was a good candidate for the unknown second gene 
promoting thrombophilia in this kindred.45 
The identification of new genes influencing the risk of venous thrombosis can 
be performed by directly focusing on venous thrombosis or by focusing on 
intermediate phenotypes, i.e. plasma concentrations of known coagulation 
factors or markers of coagulation. Elevated plasma concentrations of several 
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procoagulant factors (e.g., factor VIII, factor IX and factor XI) have been 
shown to increase the risk of venous thrombosis46-49, although no genetic 
variants underlying the elevated levels, besides ABO blood group for FVIII, 
have been discovered yet. The study of intermediate phenotypes, also known 
as quantitative traits, offers distinct advantages, as they are measured 
on a continuous scale and thus provide more information than a person’s 
disease status, which is measured on a dichotomous scale (present/absent). 
In addition, quantitative traits probably are under more direct or exclusive 
genetic control than disease outcomes. 
A first step before initiating a more detailed search for a genetic mechanism 
using linkage analysis is to determine the heritability of a certain trait (disease 
or quantitative trait). Chapter II.1 describes the results of an analysis 
performed to estimate the heritability of several hemostatic quantitative traits 
measured in blood samples from 330 members of the protein C deficient 
kindred. This analysis provided evidence for a genetic basis for the variation 
in levels of measures of thrombin activity (protein C activation peptide and 
fibrinogen peptide A), prothrombin, factor V, factor IX, protein C, protein 
Z, protein Z inhibitor, APC-PCI and APC in complex with α1-antitrypsin. 
The heritability estimates were largely similar to results found on the same 
coagulation factors in other studies.50-53 Hemostatic factors showing a large 
genetic component are the best candidates to identify the genes influencing 
the variation in the plasma concentrations of these factors by linkage analysis.
Chapter II.2 shows the evidence we found, using variance component 
linkage analysis, for two quantitative trait loci (QTLs) influencing the plasma 
concentrations of two markers of protein C activity: APC-PCI and APC-α1-
antitrypsin complexes. For plasma concentrations of APC-α1-antitrypsin 
complex measured in 135 genotyped family members, we found evidence 
suggestive for linkage (defined as a lod score between 1.9 and 3.3) on 
chromosome 19 at 34 cM (lod score 3.3). In addition, we found suggestive 
linkage evidence for plasma concentrations of APC-PCI complex in 129 
genotyped family members on chromosome 11 at 146 cM (lod score 2.6). 
However, as the linkage regions are too wide to be certain of linkage, we 
will finemap, i.e. narrow the regions on chromosomes 11 and 19, by adding 
microsatellite markers to the genome scan. In case candidate genes will be 
identified, the linkage analysis can be complemented with physical mapping 
for which single nucleotide polymorphisms (SNPs) in candidate genes are a 
first target. The search for variants will initially be focussed on coding regions 
(exons) and promotors of candidate genes as these are expected to influence 
risk of disease by variation in a quantitative trait. Candidate variants can 
subsequently be tested in association or family studies. 
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Genetic risk factors for venous thrombosis: key players or minor risk 
enhancers?
Summarizing the results of the prospective part of the EPCOT study we can 
conclude that the risk of first and recurrent venous thrombosis is increased in 
families with inherited thrombophilia, but that none of the genetic risk factors 
seems sufficient and necessary in heterozygous carriers for the development 
of venous thrombosis. However, single genetic minor risk enhancers with a 
low and incomplete penetrance can become key players in the presence of 
additional risk factors. This has been shown earlier in subjects with multiple 
genetic defects16,54,55 and has been described by Vandenbroucke et al., who 
showed a highly increased risk associated with factor V Leiden when women 
used oral contraceptives.56 Therefore, the identification of new genetic risk 
factors, even those only minimally increasing the risk, can teach us more 
about different pathways involved in venous thrombosis and gene-gene and 
gene-environment interactions. 
The search for new mutations should not be restricted to genes coding for 
hemostatic phenotypes associated with venous thrombosis. For example for 
factor VIII no genetic variations in clotting factor genes, such as of factor 
VIII or its carrier protein von Willebrand factor, have been found that are 
associated with plasma concentrations, whereas a large genetic basis for the 
variation in these levels was found.57 In addition, in the LETS study evidence 
was found for a clustering pattern of pro- and anticoagulant factors by using 
principal-components analysis to explain relationships among correlated levels 
of coagulation factors.58 This suggests the involvement of genes influencing 
the levels of several coagulation factors by modulating post-transcriptional 
or post-translational processes. As these pleiotropically acting genes will not 
be identified by the direct analysis of hemostatic candidate genes, linkage 
analysis seems to be the method of choice to identify these new genetic risk 
factors. However, despite the success of linkage analysis in identifying loci 
underlying diseases showing a Mendelian inheritance pattern (i.e. disorders 
caused by a single defective gene), linkage analysis is believed to be less 
powerful in finding genes with small effects underlying complex diseases.59-
61 As many genes are involved in the onset of a complex disease, family 
members who carry a single disease gene will not automatically develop 
disease, which precludes the identification of all carriers of the disease allele 
within a family: a prerequisite for efficiently performing linkage analysis. 
We still are optimistic about applying linkage analysis to localize disease 
loci and QTLs in the protein C deficient kindred because only a few genes 
seem responsible for venous disease as most thrombotic episodes could be 
attributed to the co-occurrence of a second gene with protein C deficiency44, 
and because of the high heritabilies found for quantitative traits in this kindred 
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(Chapter II.1). In addition, our study is thought to have a high relative 
efficiency (91%) for QTL mapping.62 However, the main challenge will be 
replicating our linkage analysis results: disease alleles or alleles influencing 
quantitative traits might be only highly prevalent or penetrant in the protein 
C deficient kindred and might not show an association with disease or 
quantitative traits in population-based association studies. Genome-wide 
association studies might be more powerful to search randomly for genes, 
but at this point these studies are still too expensive and time-consuming, 
although this technological limitation could be overcome in the near future.59-
61 Until then, linkage analysis remains the only available analysis that allows 
scanning without an a priori hypothesis for new genes. The ultimate goal of 
extending our knowledge on genetic risk factors for venous thrombosis is not 
to apply gene-therapy, but to determine for which genetic risk factors patients 
should be screened, to inform patients on potential risk situations, and to 
provide optimal prophylactic treatment in those situations when assumed 
necessary. Manipulating the environment remains the most effective means to 
control complex common diseases. 
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Veneuze trombose, oftewel ongewenste stolselvorming in de aderen die het 
bloed naar het hart vervoeren, is een frequente aandoening met jaarlijks 
één à twee nieuwe patiënten op de 1000 personen. Het komt meestal voor 
in de diepe aderen van het been, of in de longen na het loskomen van een 
stukje van het stolsel (longembolie). Er zijn vele factoren bekend die het 
risico op een veneuze trombose verhogen, zoals erfelijke afwijkingen in 
het stollingssysteem, hormonale veranderingen (bijv. bij zwangerschap of 
gebruik van de pil), weinig beweging (bijv. door dwarslaesie of gips), en 
orthopedische operaties. Van de patiënten die zich melden met een eerste 
veneuze trombose heeft ongeveer een kwart naaste familie met dezelfde 
aandoening. Erfelijke defecten die de kans op veneuze trombose verhogen 
zijn o.a. tekorten van de antistollingsfactoren proteïne C, proteïne S en 
antitrombine, en de factor V Leiden en protrombine G20210A mutatie. Zoals 
bij de meeste veel voorkomende ziekten is één risicofactor niet voldoende 
om de ziekte te veroorzaken. Zo is aangetoond dat veneuze trombose vaker 
voorkomt bij dragers van een erfelijk stollingsdefect met veneuze trombose in 
de familie dan bij dragers zonder veneuze trombose in de familie. In families 
met een stollingsdefect en een verhoogde aanleg voor veneuze trombose 
(trombofilie) wordt daarom de aanwezigheid van meer dan één genetisch 
defect verondersteld. Studies waarin het risico op veneuze trombose is 
onderzocht in families met trombofilie zijn schaars omdat familiaire defecten 
weinig voorkomen, met name in de natuurlijke antistollingsfactoren. Goede 
risicoschattingen zijn echter hard nodig om richtlijnen te kunnen formuleren 
voor het testen op deze defecten en het beslissen over het voorschrijven 
van preventieve antistollingstherapie in deze families. In 1994 is daarom 
een onderzoek begonnen om het risico op veneuze trombose te bepalen 
in individuen met erfelijke trombofilie: de “European Prospective Cohort 
study On Thrombophilia” (EPCOT). Onderzoekers uit verschillende Europese 
trombosecentra met expertise op het gebied van trombofilie deden mee aan 
dit onderzoek. In het eerste deel van dit proefschrift worden de resultaten 
beschreven van het EPCOT-onderzoek wat betreft het risico op een eerste of 
tweede trombose in deelnemers met een erfelijke tromboseneiging (Hoofdstuk 
I.1-3). Daarnaast hebben we binnen EPCOT gekeken naar het risico op 
miskramen bij vrouwen met een erfelijk stollingsdefect (Hoofdstuk I.4). 
Hoofdstuk II richt zich op het zoeken naar nieuwe nog onbekende genetische 
factoren die de kans op veneuze trombose verhogen. Slechts in 13% van 
de families met trombofilie zijn minstens twee defecten bekend, terwijl de 
aanwezigheid van meer dan één defect in alle families wordt verondersteld. 
De nu bekende defecten verklaren dus nog maar een klein deel van het risico 
op trombose in families met trombofilie. 
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Het risico op veneuze trombose en miskramen in het EPCOT 
onderzoek
In totaal werden 2838 deelnemers geïncludeerd in het EPCOT onderzoek, 
van wie 1626 met erfelijke trombofilie door de factor V Leiden mutatie 
of door deficiënties in proteïne C, proteïne S of antitrombine. De overige 
1212 deelnemers waren vrienden of partners die werden onderzocht als 
vergelijkingsgroep (controlepersonen). Hoofdstuk I.1 beschrijft retrospectief 
de kans op trombose bij de deelnemers; vanaf de geboorte tot aan het begin 
van de studie. Van de 846 familieleden met erfelijke trombofilie die niet 
vanwege een trombose waren getest hadden 139 familieleden (16%) een 
trombose gehad voor inclusie in het onderzoek vergeleken met 15 van de 
1212 controlepersonen (1%). Van de deelnemers met trombose hadden 58 
familieleden (42%) en 2 controlepersonen (13%) al meer dan één episode 
doorgemaakt. De incidentie oftewel het jaarlijks aantal ziektegevallen voor 
inclusie in de studie was 4,4 per 1000 familieleden en 0,3 per 1000 controle 
personen. De incidentie van 0,3 per 1000 ligt dus iets lager dan de incidentie 
die werd gevonden in de literatuur voor de bevolking van één à twee nieuwe 
patiënten per 1000 mensen per jaar. De hoogste incidentie werd gevonden 
voor familieleden die meer dan één defect hadden (8,4 per 1000 per jaar). 
Voor familieleden met één bekend defect werd het hoogste risico gevonden bij 
familieleden met proteïne S deficiëntie (7,1 per 1000), en het laagste risico bij 
familieleden met de factor V Leiden mutatie (1,5 per 1000). 
Na inclusie werden deelnemers gemiddeld 5,5 jaar prospectief gevolgd. Bij het 
begin van het onderzoek waren 575 familieleden en 1118 controlepersonen 
trombose-vrij en antistollingstherapie-vrij, van wie 26 familieleden (4,5%) 
en 7 controles (0,6%) een eerste trombose kregen in de vervolgjaren na de 
inclusie (Hoofdstuk I.2). Bij 15 familieleden (58%) en 3 controlepersonen 
(43%) ontstond de trombose in afwezigheid van bekende risicofactoren zoals 
operaties, zwangerschap of inactiviteit. De incidentie van een eerste trombose 
was 0,8% per jaar in familieleden en 0,1% per jaar in controle personen. 
Net als in hoofdstuk I.1 verschilden de incidenties per genetisch defect: de 
hoogste incidentie werd gevonden bij familieleden met antitrombine deficiëntie 
(1,7%/jaar) of meer dan één defect (1,6%/jaar), en de laagste incidentie 
bij dragers van factor V Leiden (0,1%/jaar). We vonden dus een hogere 
incidentie voor een eerste trombose in de analyse vanaf de inclusie (hoofdstuk 
I.2) dan in de analyse van gegevens over trombose voor de inclusie 
(hoofdstuk I.1). De incidenties uit hoofdstuk I.1 zijn echter waarschijnlijk 
lager, omdat de tijd tussen geboorte en inclusie in de studie werd genomen en 
het risico op trombose onder de 15 jaar te verwaarlozen is.
Hoofdstuk I.3 beschrijft de kans op een tweede trombose in de vervolgjaren 
na de start van de studie in familieleden met trombofilie en één veneuze 
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trombose voor het begin van de studie. Van de 180 patiënten die geen 
langdurige antistolling ontvingen, kregen 44 (24%) een tweede trombose 
vergeleken met 7 van de 124 (6%) patiënten die wel langdurige antistolling 
ontvingen. De incidentie zonder langdurige antistolling was 5,0% per jaar en 
dus veel hoger dan de incidentie van een eerste trombose (hoofdstuk I.2). 
De incidentie was echter niet hoger dan de incidentie in de literatuur voor 
patiënten met veneuze trombose zónder een trombosegeschiedenis in de 
familie. Net als in hoofdstuk I.2 werd de laagste incidentie gevonden in factor 
V Leiden dragers, en de hoogste incidentie bij individuen met antitrombine 
deficiëntie. De incidentie werd met 80% verlaagd door langdurige antistolling 
en was daarmee bijna gelijk aan de incidentie van een eerste trombose, maar 
het gebruik van langdurige antistollingstherapie resulteerde in een risico op 
ernstige bloedingen van 0.8% per jaar. 
Uit de voorgaande hoofdstukken kan worden afgeleid dat er geen duidelijk 
voordeel bestaat in het voorschrijven van langdurige antistollingstherapie bij 
mensen met een erfelijk stollingsdefect. Ten eerste weegt het risico op een 
eerste trombose bij mensen met erfelijke trombofilie niet op tegen het risico 
op bloedingen tijdens het gebruik van antistolling zoals beschreven in de 
literatuur (1-3%). Ten tweede is het herhalingsrisico even groot bij mensen 
met of zonder een stollingsdefect en wordt voor de laatste groep geen 
langdurige antistollingstherapie voorgeschreven.
Naast het risico op trombose hebben we ook gekeken naar het risico op 
miskramen bij vrouwen met erfelijke trombofilie. In totaal werden 90 vrouwen 
die geen miskraam hadden gehad voor het begin van de studie zwanger in 
de jaren na de studie inclusie: 39 vrouwen met trombofilie en 51 controle 
vrouwen. Zeven van de 39 vrouwen met trombofilie (20%) en 7 van de 51 
controle vrouwen (14%) kregen een miskraam. Er was geen verschil in de 
kans op een miskraam per type defect. De kans op een goede afloop van de 
zwangerschap was dus hoog voor beide groepen vrouwen.
Zoektocht naar nieuwe genen in een familie met proteïne C deficiëntie 
Sinds 1985 wordt een grote familie (ongeveer 800 leden) met proteïne C 
deficiëntie gevolgd aan de universiteit van Vermont (USA). Ongeveer 25% van 
de familieleden heeft proteïne C deficiëntie door een bepaalde mutatie (3363C 
mutatie) in het proteïne C gen, en ongeveer 25% van deze dragers ontwikkelt 
een veneuze trombose. In 1998 werd bewijs gevonden voor de aanwezigheid 
van een onbekend gen dat samen met het proteïne C gen het ontstaan van 
veneuze trombose in de familie voor een groot deel verklaart. Er werden 
verschillende kandidaten getest, waaronder factor V Leiden en protrombine 
G20210A, maar zonder resultaat. Voor de protrombine G20210A mutatie was 
dit een onverwachte bevinding, aangezien de mutatie in deze familie vaker 
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voorkomt dan in de algemene bevolking (bij 13% in plaats van 2-4%) en 
deze mutatie vaak het risico op trombose verhoogt in combinatie met andere 
stollingsdefecten zoals factor V Leiden. De protrombine G20210A mutatie 
wordt in de literatuur geassocieerd met een verhoogde trombine aanmaak. 
Trombine activeert proteïne C, dus de protrombine G2010A mutatie zou via 
een verhoogde trombine aanmaak een gunstig effect kunnen hebben op de 
activering van proteïne C in familieleden met proteïne C deficiëntie. Door het 
complex van proteïne C met een remmer te meten als maat voor proteïne C 
activering testten we deze hypothese. We vonden echter geen verband tussen 
de protrombine G20210A variant en proteïne C activering in 195 familieleden, 
van wie 55 de proteïne C mutatie droegen en 44 de protrombine G20210A 
mutatie (Hoofdstuk I.5). 
Voor de identificatie van nieuwe stollingsgerelateerde genen in deze proteïne 
C deficiënte familie richtten we ons op genen die de concentraties van 
stollingsfactoren en dus indirect de kans op veneuze trombose zouden kunnen 
beïnvloeden. Ten eerste hebben we bepaald of er wel een genetische basis is 
voor de variatie in de concentraties van verschillende stollingsfactoren in het 
bloed in 330 familieleden (Hoofdstuk II.1). We vonden bewijs voor een redelijk 
grote genetische basis voor o.a. concentraties van protrombine, factor V, 
factor IX, proteïne C en proteïne Z. Stollingsfactoren met een grote genetische 
component zijn de beste kandidaten voor het identificeren van genen die de 
concentraties in het bloed van deze stollingsfactoren beïnvloeden. Hoofdstuk 
II.2 toont de resultaten van een studie waarbij we genen hebben geprobeerd 
te koppelen aan de concentraties in het bloed van complexen die worden 
gemeten als maat voor proteïne C activiteit, namelijk geactiveerd proteïne 
C gebonden aan twee proteïne C remmers. Door in het genoom van elk 
individu op verschillende plaatsen een marker te bepalen, kan worden bepaald 
of de concentratie van een stollingsfactor gelijk wordt overgeërfd met een 
bepaalde marker waarvan de plaats bekend is. Met deze methode vonden 
we een aanwijzing voor een koppeling tussen een marker op chromosoom 
19 en concentraties van het complex van geactiveerd proteïne C met de 
remmer α1-antitrypsine. Daarnaast vonden we een koppeling tussen een 
marker op chromosoom 11 en concentraties van het complex van geactiveerd 
proteïne C met “proteïne C remmer”. Door het toevoegen van markers in het 
geïdentificeerde gebied kan vervolgens in meer detail worden nagegaan of er 
werkelijk een gen gekoppeld kan worden aan de gemeten concentraties. 
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Genetische risicofactoren voor veneuze trombose: schuldig of 
medeplichtig?
Uit de resultaten van hoofdstuk I.1 en I.2 kan worden geconcludeerd 
dat de kans op veneuze trombose verhoogd is in dragers van familiaire 
stollingsdefecten, maar dat de aanwezigheid van de meeste defecten 
niet onherroepelijk leidt tot het ontstaan van een veneuze trombose. De 
aanwezigheid van andere genetische risicofactoren of omgevingsfactoren kan 
het effect van deze stollingsdefecten op de kans op veneuze trombose hebben 
beïnvloed, zoals kan worden afgeleid uit het hoge risico op veneuze trombose 
dat werd gevonden in hoofdstuk I.2 en I.3 bij mensen die drager waren van 
verscheidene defecten. De identificatie van nieuwe genetische risicofactoren 
kan ons dus meer leren over hoe de interactie tussen verschillende 
risicofactoren uiteindelijk leidt tot het ontstaan van een trombose. Het 
uiteindelijke doel van het vinden van nieuwe genetische risicofactoren voor 
trombose is niet om gentherapie te kunnen toepassen, maar om informatie 
te krijgen over op welke genetische risicofactoren het best kan worden 
getest en om patiënten te kunnen informeren over eventuele risicosituaties 
en de mogelijkheden om in die situaties een trombose te voorkomen. Het 
beïnvloeden van omgevingsfactoren blijft nog altijd de meest effectieve 
methode om ziekte te voorkomen.
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